

NBER WORKING PAPER SERIES

UPCODING: EVIDENCE FROM MEDICARE ON SQUISHY RISK ADJUSTMENT

Michael Geruso
Timothy Layton

Working Paper 21222
<http://www.nber.org/papers/w21222>

NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
May 2015, Revised April 2018

We thank Colleen Carey, Joshua Gottlieb, and Amanda Kowalski for serving as discussants, as well as seminar participants at the 2014 Annual Health Economics Conference, the 2014 American Society of Health Economists Meeting, the BU/Harvard/MIT Health Economics Seminar, Boston University, Emory University, Harvard Medical School, the NBER Public Economics Meeting 2015, the University of Illinois at Chicago, RTI, the Southeastern Health Economics Study Group, and the University of Texas at Austin for useful comments. We also thank Chris Afendulis, Marika Cabral, Vilsa Curto, David Cutler, Francesco Decarolis, Liran Einav, Randy Ellis, Keith Ericson, Amy Finkelstein, Austin Frakt, Craig Garthwaite, Jonathan Gruber, Jonathan Kolstad, Tom McGuire, Hannah Neprash, Joe Newhouse, and Daria Pelech for assistance obtaining data and useful conversations. Layton gratefully acknowledges financial support from the National Institute of Mental Health (T32-019733). Geruso gratefully acknowledges financial support from the Robert Wood Johnson Foundation and from grants 5 R24 HD042849 and 5 T32 HD007081 awarded to the Population Research Center at the University of Texas at Austin by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

NBER working papers are circulated for discussion and comment purposes. They have not been peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications.

© 2015 by Michael Geruso and Timothy Layton. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source.

Upcoding: Evidence from Medicare on Squishy Risk Adjustment
Michael Geruso and Timothy Layton
NBER Working Paper No. 21222
May 2015, Revised April 2018
JEL No. H42,H51,I1,I13,I18

ABSTRACT

In most US health insurance markets, plans face strong incentives to “upcode” the patient diagnoses they report to the regulator, as these affect the risk-adjusted payments plans receive. We show that enrollees in private Medicare plans generate 6% to 16% higher diagnosis-based risk scores than they would under fee-for-service Medicare, where diagnoses do not affect most provider payments. Our estimates imply upcoding generates billions in excess public spending and significant distortions to firm and consumer behavior. We show that coding intensity increases with vertical integration, suggesting a principal-agent problem faced by insurers, who desire more intense coding from the providers with whom they contract.

Michael Geruso
University of Texas at Austin
Department of Economics
1 University Station C3100
Austin, TX 78712
and NBER
mike.geruso@austin.utexas.edu

Timothy Layton
Harvard Medical School
Department of Health Care Policy
180 Longwood Avenue
Boston, MA 02115
and NBER
layton@hcp.med.harvard.edu

Diagnosis-based subsidies have become an increasingly important regulatory tool in US health insurance markets and public insurance programs. Between 2003 and 2014, the number of consumers enrolled in a market in which an insurer’s payment is based on the consumer’s diagnosed health conditions increased from almost zero to over 50 million, including enrollees in Medicare, Medicaid, and state and federal Health Insurance Exchanges. These diagnosis-based payments to insurers are known as risk adjustment, and their introduction has been motivated by a broader shift away from public fee-for-service health insurance programs and towards regulated private markets (Gruber, 2017). By compensating insurers for enrolling high expected-cost consumers, risk adjustment weakens insurer incentives to engage in cream-skimming—that is, inefficiently distorting insurance product characteristics to attract lower-cost enrollees as in Rothschild and Stiglitz (1976).¹

The intuition underlying risk adjustment is straightforward: diagnoses-based transfer payments can break the link between the insurer’s expected costs and the insurer’s expected profitability of enrolling a chronically ill consumer. But the mechanism assumes that a regulator can objectively measure each consumer’s health state. In practice in health insurance markets, regulators infer an enrollee’s health state from the diagnoses reported by physicians during their encounters with the enrollee. This diagnosis information, usually captured in bills sent from the provider to the insurer, is aggregated into a risk score on which a regulatory transfer to the insurer is based. Higher risk scores trigger larger transfers. Insurers thus have a strong incentive to “upcode” reported diagnoses and risk scores, either via direct insurer actions or by influencing physician behavior.² By upcoding, we mean activities that range from increased provision of diagnostic services that consumers value to outright fraud committed by the insurer or provider. The extent of such practices is of considerable policy, industry, and popular interest.³ Nonetheless, little is known about the extent of upcoding or its implications: The few recent studies examining the distortionary effects of risk adjustment (e.g., Brown et al., 2014, Carey, 2014, and Einav et al., 2015) have all taken diagnosis coding as fixed for a given patient, rather than as an endogenous outcome potentially determined by physician and insurer strategic behavior. In contrast, in this paper we show that endogenous diagnosis coding is an empirically important phenomenon that has led to billions in annual overpayments by the federal

¹For example, during our study period, a diagnosis of *Diabetes with Acute Complications* in Medicare Advantage incrementally increased the payment to the MA insurer by about \$3,400 per year. This amount was set by the regulator to equal the average incremental cost associated with this diagnosis in the traditional fee-for-service Medicare program.

²For example, insurers can pay physicians on the basis of codes assigned, rather than for visits and procedures.

³See, for example, CMS (2010); Government Accountability Office (2013); Kronick and Welch (2014); Schulte (2014).

government, as well as significant distortions to consumer choices.

We begin by constructing a stylized model to assess the effects of upcoding in a setting where private health plans compete for enrollees against a public option. We use the model to show that when risk scores (and thus plan payments) are endogenous to the contract details chosen by the private plans, three types of distortions are introduced. First, a wedge is introduced between the efficient private contract and the private contract offered in equilibrium, with equilibrium contracts characterized by levels of coding services (and, in some cases, other healthcare services) that are too high in the sense that the marginal social cost of the services exceeds the marginal social benefit. Second, the higher levels of coding in the private plans increases government subsidies paid to these plans, increasing the cost of the program to taxpayers. Third, these differential subsidies cause equilibrium plan prices not to reflect the underlying social resource cost of enrolling a consumer in the plan, causing consumer choices to be inefficiently tilted toward the plans that code most intensely. These results hold regardless of the legality of plans' and physicians' coding-related behaviors and regardless of whether consumers attach positive value to coding services.

We investigate the empirical importance of upcoding in the context of Medicare. For hospital and physician coverage, Medicare beneficiaries can choose between a traditional public fee-for-service (FFS) option and enrolling with a private insurer through Medicare Advantage (MA). In the FFS system, most reimbursement is independent of recorded diagnoses. Payments to private MA plans are capitated with diagnosis-based risk adjustment. As illustrated by our model, although the incentive for MA plans to code intensely is strong, doing so is not costless and a plan's response to this incentive depends on its ability to influence the providers that assign the codes. Thus, whether and to what extent coding differs between the MA and FFS segments of the market is an empirical question.

The key challenge in identifying coding intensity differences between FFS and MA, or within the MA market segment across competing insurers, is that upcoding estimates are potentially confounded by adverse selection. An insurer might report an enrollee population with higher-than-average risk scores either because the consumers who choose the insurer's plan are in worse health (selection) or because for the same individuals, the insurer's coding practices result in higher risk scores (upcoding). We develop an approach to separately identify selection and coding differences in equilibrium. The core insight of our research design is that if the same individual would generate a different risk score under two insurers and if we observe an exogenous shift in the market shares

of the two insurers, then we should also observe changes in the *market-level* average of reported risk scores. Such a pattern could not be generated or rationalized by selection, because selection can affect only the sorting of risk types across insurers within the market, not the overall market-level distribution of reported risk scores.⁴ A key advantage of our strategy is that the data requirements are minimal, and it could be easily implemented in future assessments of coding in Health Insurance Exchanges or state Medicaid programs. Our focus on empirically disentangling upcoding from selection distinguishes our study from prior, policy-oriented work investigating upcoding in the context of Medicare (e.g. [Kronick and Welch, 2014](#)).⁵

To identify coding differences, we exploit large and geographically heterogeneous increases in MA enrollment within county markets that began in 2006 following the Medicare Modernization Act. We simultaneously exploit an institutional feature of the MA program that causes risk scores to be based on prior year diagnoses. This yields sharp predictions about the timing of effects relative to changing market penetration in a difference-in-differences framework. Using the rapid within-county changes in penetration that occurred over our short panel, we find that a 10 percentage point increase in MA penetration leads to a 0.64 percentage point increase in the reported average risk score in a county. This implies that MA plans generate risk scores for their enrollees that are on average 6.4% larger in the first year of MA enrollment than what those same enrollees would have generated under FFS. This is a large effect. A 6.4% increase in market-level risk is equivalent to 6% of all consumers in a market becoming paraplegic, 11% developing Parkinson’s disease, or 39% becoming diabetic. While these effects would be implausibly large if they reflected rapid changes to actual population health, they are plausible when viewed as reflecting only endogenous coding behavior. Our results also suggest that the MA coding intensity differential may ratchet up over time, reaching 8.7% by the second year of MA enrollment.

To complement our main identification strategy at the market level, we also provide individual-level evidence for a sample of Massachusetts residents. We track risk scores within consumers as

⁴The idea that changes in a population average outcome can be used to infer marginal impacts is well-known in applied econometrics, with applications including [Gruber, Levine and Staiger \(1999\)](#), [Einav, Finkelstein and Cullen \(2010\)](#), and [Chetty, Friedman and Rockoff \(2014\)](#).

⁵[Kronick and Welch \(2014\)](#) provide evidence that risk scores have grown more rapidly over time in MA relative to FFS. Other analyses, including [Government Accountability Office \(2013\)](#), follow a similar strategy. An important difference from our analysis is that comparing the growth rate of risk scores in the FFS population to the growth rate of risk scores in the MA population would not be robust to selection on health. Further, by focusing on differences in risk score growth rates rather than levels, the [Kronick and Welch \(2014\)](#) strategy cannot estimate a parameter of interest here—the difference in risk scores and implied payments for a consumer choosing MA versus FFS. Nonetheless, it is the strongest prior evidence that MA codes intensively relative to FFS.

they transition from an employer or individual-market commercial plan to Medicare at the age 65 eligibility threshold. We present event study graphs comparing the groups that eventually choose MA and FFS. We show that during the years prior to Medicare enrollment when both groups were enrolled in similar employer and commercial plans, level differences in coding intensity were stable. Following Medicare enrollment, however, the difference in coding intensity between the MA and FFS groups spikes upward, providing transparent visual evidence of a coding intensity effect of MA. This entirely separate identification strategy based on the Medicare eligibility threshold confirms the size of our estimates from the main analysis and allows us to examine mechanisms and individual-level heterogeneity underlying the aggregate MA/FFS coding intensity differences.

These empirical findings have specific implications for the Medicare program as well as broader implications for the regulation of private insurance markets. Medicare is the costliest public health insurance program in the world and makes up a significant fraction of US government spending. Even relative to a literature that has consistently documented phenomena leading to significant overpayments to or gaming by private Medicare plans (e.g., [Ho, Hogan and Scott Morton, 2014](#); [Decarolis, 2015](#); [Brown et al., 2014](#)), the size of the overpayment due to manipulable coding is striking.⁶ Absent a coding correction, our estimates imply excess payments of around \$10.2 billion to Medicare Advantage plans annually, or about \$650 per MA enrollee per year. In 2010, toward the end of our study period, the Center for Medicaid and Medicare Services (CMS) began deflating MA risk payments due to concerns about upcoding, partially counteracting these overpayments.⁷ To provide further context for the size of the effects that we estimate, we draw on estimates of demand response from the prior literature on MA. These estimates imply that completely removing the hidden subsidy due to upcoding would reduce the size of the MA market by 17% to 33%, relative to a counterfactual in which CMS made no adjustment.

We view our results as addressing an important gap in the literature on adverse selection and the public finance of healthcare. Risk adjustment is the most widely implemented regulatory response to adverse selection. A few recent studies, including [Curto et al. \(2014\)](#) and [Einav and Levin \(2014\)](#), have

⁶[Decarolis \(2015\)](#) investigates how Medicare Part D insurers manipulate bids to game payment formulas and drive up payments; [Ho, Hogan and Scott Morton \(2014\)](#) estimate excess public spending arising from consumers' inattention to health plan choice and insurers' endogenous responses to that inattention; and [Brown et al. \(2014\)](#) estimate the increase in excess payments to MA plans due to uncompensated favorable selection following the implementation of risk adjustment. [Brown et al. \(2014\)](#) find the largest public spending impacts, at \$317 per enrollee per year.

⁷In 2010 CMS began deflating MA risk scores via a "coding intensity adjustment" factor. This deflator was set at 3.41% in 2010; was increased to 4.91% in 2014; and is set to increase again to 5.91% in 2018. Our results indicate that even the most recent deflation is both too small and fails to account for large coding differences across MA plan types.

begun to recognize the potential importance of upcoding, but the empirical evidence is underdeveloped. The most closely related prior work on coding has shown that patients' reported diagnoses in FFS Medicare vary with the local practice style of physicians (Song et al., 2010) and that coding responds to changes in how particular codes are reimbursed by FFS Medicare for inpatient hospital stays (Dafny, 2005; Sacarny, 2014). Ours is the first study to model the welfare implications of differential coding patterns across insurers and to provide empirical evidence of the size and determinants of these differences.

Our results also provide a rare insight into the insurer-provider relationship. Because diagnosis codes ultimately originate from provider visits, insurers face a principal-agent problem in contracting with physicians. We find that coding intensity varies significantly according to the contractual relationship between the physician and the insurer. Fully vertically integrated (i.e., provider owned) plans generate 16% higher risk scores for the same patients compared to FFS, nearly triple the effect of non-integrated plans. This suggests that the cost of aligning physician incentives with insurer objectives may be significantly lower in vertically integrated firms. These results connect to a long literature concerned with the internal organization of firms (Grossman and Hart, 1986) and the application of these ideas to the healthcare industry (e.g., Gaynor, Rebitzer and Taylor, 2004 and Frakt, Pizer and Feldman, 2013), as well as to the study of the intrinsic (Kolstad, 2013) and extrinsic (Clemens and Gottlieb, 2014) motivations of physicians. Our results also represent the first direct evidence of which we are aware that vertical integration between insurers and providers may facilitate the "gaming" of health insurance payment systems. However, these results likewise raise the possibility that strong insurer-provider contracts may also facilitate other, more socially beneficial, objectives, including quality improvements through pay-for-performance incentives targeted at the level of the insurer. This is an issue of significant policy and research interest (e.g., Fisher et al., 2012; Frakt and Mayes, 2012; Frandsen and Rebitzer, 2014), but as Gaynor, Ho and Town (2015) describe in their recent review, it is an area in which there is relatively little empirical evidence.

Finally, our results connect more broadly to the economic literature on agency problems in monitoring, reporting, and auditing. Here, insurers are in charge of reporting the critical inputs that will determine their capitation payments from the regulator. But the outsourcing of regulatory functions to interested parties is not unique to this setting, with examples in other parts of the healthcare system (Dafny, 2005), in environmental regulation (Duflo, Greenstone and Ryan, 2013), in financial markets

(Griffin and Tang, 2011), and elsewhere. Our results point to a tradeoff in which the tools used to better align regulator and firm incentives in one way (here, risk adjustment to limit cream-skimming) may cause them to diverge in other ways (as coding intensity is increased to capture subsidies).

2 Background

We begin by outlining how a risk-adjusted payment system functions, though we refer the reader to van de Ven and Ellis (2000) and Geruso and Layton (2017) for more detailed treatments. We then briefly discuss how diagnosis codes are assigned in practice.

2.1 Risk Adjustment Background

Individuals who are eligible for Medicare can choose between the FFS public option or coverage through a private MA plan. All Medicare-eligible consumers in a county face the same menu of MA plan options at the same prices. Risk adjustment is intended to undo insurer incentives to avoid sick, high cost patients by tying subsidies to patients' health status. By compensating the insurer for an enrollee's expected cost on the basis of their diagnosed health conditions, risk adjustment can make all potential enrollees—regardless of health status—equally profitable to the insurer on net (in expectation) even when premiums are not allowed to vary across consumer types. This removes plan incentives to distort contract features in an effort to attract lower-cost enrollees, as in Rothschild and Stiglitz (1976) and Glazer and McGuire (2000). Risk adjustment was implemented in Medicare starting in 2004 and was fully phased-in by 2007.

Formally, plans receive a risk adjustment subsidy, S_i , from a regulator for each individual i they enroll. The risk adjustment subsidy supplements or replaces premiums, p , paid by the enrollee with total plan revenues given by $p + S_i$. In Medicare Advantage, S_i is calculated as the product of an individual's risk score, r_i , multiplied by some base amount, \bar{C} , set by the regulator: $S_i = \bar{C} \cdot r_i$.⁸ In practice in our empirical setting, \bar{C} is set to be approximately equal to the mean cost of providing FFS in the local county market for a typical-health beneficiary, or about \$10,000 per enrollee per year on average in 2014.⁹

⁸Across market settings, \bar{C} can correspond to the average premium paid in the full population of enrollees, as in the ACA Exchanges, or some statutory amount, as in Medicare Advantage.

⁹Historically, county benchmarks have been set to capture the cost of covering the "national average beneficiary" in the FFS program in that county, though Congress has made many ad hoc adjustments over time. In practice, benchmarks can

The risk score is determined by multiplying a vector of risk adjusters, x_i , by a vector of risk adjustment coefficients, Λ . Subsidies are therefore $S_i = \bar{C} \cdot x_i \Lambda$. Risk adjusters, x_i , typically consist of a set of indicators for demographic groups (age-by-sex cells) and a set of indicators for condition categories, which are based on diagnosis codes contained in health insurance claims. In Medicare, as well as the federal Health Insurance Exchanges, these indicators are referred to as Hierarchical Condition Categories (HCCs). Below, we refer to x_i as “conditions” for simplicity. The coefficients Λ capture the expected incremental impact of each condition on the insurer’s expected costs, as estimated by the regulator in a regression of total spending on the vector x_i in some reference population (in this case FFS). Coefficients Λ are normalized by the regulator so that the average risk score is equal to 1.0 in the relevant reference population. In Medicare, risk scores for payment in year t are based on diagnoses in $t - 1$. The important implicit assumption underlying the functioning of risk adjustment is that conditions, x_i , do not vary according to the plan in which a consumer is enrolled. In other words, diagnosed medical conditions are properties of individuals, not individual \times plan matches.

2.2 Diagnosis Coding in Practice

Typically, the basis for all valid diagnosis codes is documentation from a face-to-face encounter between the provider and the patient. During an encounter like an office visit, a physician takes notes, which are passed to the billing staff in the physician’s office. Billers use the notes to generate a claim, which includes diagnosis codes, that is sent to the insurer for payment. The insurer pays claims and over time aggregates all of the diagnoses associated with an enrollee. Diagnoses are then submitted to the regulator, who generates a risk score on which payments to the insurer are based.

There are many ways for plans and providers to influence the diagnoses that are reported to the regulator. Although we reserve a more complete description of these mechanisms to Appendix Section A.2 and Figure A1, we note that insurers can structure contracts with physician groups such that the payment to the group is a function of the risk-adjusted payment that the insurer itself receives from the regulator. This directly passes through coding incentives to the physician groups. Additionally, even after claims and codes are submitted to the insurer for an encounter, the insurer or its contractor may perform a chart review—automatically or manually reviewing physician notes and patient charts to add new codes that were not originally translated to the claims submitted by

vary from such historical costs and can also vary somewhat by plan due to a “bidding” process. See Appendix A.1 for full details.

the submitting physician’s office. Such additions may be known only to the insurer who edits the reports sent to the regulator, with no feedback regarding the change in diagnosis being sent to the physician or her patient.

Plans may also directly encourage their enrollees to take actions that result in more intensive coding, using financial incentives (including, simply, lower copays for evaluation and management visits) or incentivizing enrollees to complete annual “risk assessments.” These are inexpensive to the insurer, but can be used to document diagnoses that would otherwise have gone unrecorded in the claims.¹⁰ Further, if an insurer observes that an enrollee who has previously received diagnoses for a code-able condition has not visited a physician in the current plan year (as risk scores are based on single-year diagnosis reports), the insurer can directly intervene by proactively contacting the enrollee and sending a physician or nurse to the enrollee’s home. The visit is necessary in order to code the relevant, reimbursable diagnoses for the current plan year and relatively low cost. As we discuss in Section 8, this issue is of particular concern to the Medicare regulator, CMS, as these visits, often performed by third-party contractors, appear to often be unmoored from any follow-up care or even communication with the patient’s normal physician.

None of the insurer activities targeted at diagnosis coding take place in FFS because providers under the traditional system are paid directly by the government, and the basis of these payments outside of hospital settings is procedures, not diagnoses. This difference in incentive structure between FFS and MA makes Medicare a natural setting for studying the empirical importance of differential coding intensity.

3 Model of Risk Adjustment with Endogenous Coding

In this section, we present a stylized model of firm behavior in a competitive insurance market where payments are risk adjusted. The model illustrates how distortions to public spending, consumers’ plan choices, and insurers’ benefit design can arise if risk scores are endogenous to a plan’s behavior.

¹⁰Note that the supply-side tools often advocated for in the context of preventative managed care—such as proactive health risk assessments and outreach to chronically-ill patients—can serve to inflate risk scores. This is true regardless of whether such patient management is motivated by increasing risk adjustment revenue or by patient health concerns.

3.1 Setup

We consider an insurance market similar to Medicare, where consumers choose between a public option plan (FFS) and a uniform private plan alternative offered by insurers in a competitive market (MA). An MA plan consists of two types of services and a price: $\{\delta, \gamma; p\}$. Coding services, δ , include activities like insurer chart review. These services affect the probability that diagnoses are reported. We also allow them to impact patient utility. All other plan details are rolled up into a composite healthcare service, γ . We allow that *any* healthcare service or plan feature may impact reported diagnoses. For example, zero-copay specialist visits may alter the probability that a consumer visits a specialist and thus the probability that a marginal (correct) diagnosis is recorded.¹¹ Services δ and γ are measured in the dollars of cost they impose on the MA plan.

Denote the consumer valuations of δ and γ in dollar-metric utility as $v(\delta)$ and $w(\gamma)$, respectively. We assume utility is additively separable in v and w with $v' > 0$, $w' > 0$, $v'' < 0$, and $w'' < 0$. The FFS option offers reservation utility of \bar{u} for the mean consumer. Its price is zero. A taste parameter, σ_i , which is uncorrelated with net-of-risk adjustment costs, distinguishes consumers with idiosyncratic preferences over the MA/FFS choice. The purpose of the assumption of orthogonality between the taste parameter and costs is to simplify the exposition of the consequences of upcoding. The conclusions we draw from this stylized model do not rely on this assumption.¹² Utility of the MA plan is thus $v(\delta) + w(\gamma) + \sigma_i$. Using ζ_i to capture mean zero ex ante health risk that differs across consumers, expected costs in MA are $c_{i,MA} = \delta + \gamma + \zeta_i$.

To narrow focus here on the distortions generated by upcoding even when risk adjustment succeeds in perfectly in counteracting selection, we make two simplifying assumptions. First, we assume that consistent with the regulatory intent of risk adjustment, there is no uncompensated selection after risk adjustment payments are made: Risk adjustment payments net out idiosyncratic health risk in expectation, allowing us to ignore the mean zero ζ_i term when considering firm incentives, so that

¹¹The distinguishing characteristic of δ versus γ is the degree of responsiveness of risk scores to each service type. We assume coding services have greater marginal impacts on coding ($\frac{\partial \rho}{\partial \delta} > \frac{\partial \rho}{\partial \gamma}$) at the levels chosen optimally or in a competitive equilibrium. An alternative formulation with three services: services affecting coding only; affecting patient utility only; affecting both utility and coding leads to the same results.

¹²The primary reason this assumption greatly simplifies exposition is that it allows a single price to sort consumers efficiently across plans. In a more general setting, no single price can sort consumers efficiently, as in [Bundorf, Levin and Mahoney \(2012\)](#) and [Geruso \(2017\)](#). Such forms of selection add complexity to describing the choice problem without providing additional insights into the consequences of coding differences for consumer choices. This assumption also intentionally rules out phenomena like selection on moral hazard ([Einav et al., 2013](#)), which would further complicate exposition while adding little in terms of insight into the consequences of upcoding.

expected (net) marginal costs are equal to expected (net) average costs and are $\delta + \gamma$. Solely to simplify proofs and exposition, we assume further that there is no sorting by health status across plans in equilibrium. This implies that the mean risk score within the MA plan is 1.¹³

MA plans charge a premium p and receive a per-enrollee subsidy, S_i , that is a function of the risk score, $r_{i,MA}$, the plan reports. Following the institutional features of Medicare, $S_i = \bar{C} \cdot r_{i,MA}$, where \bar{C} is a base payment equal to the cost of providing FFS to the typical health Medicare beneficiary in the local market. Defining $\rho_i(\delta, \gamma) \equiv r_{i,MA} - r_{i,FFS}$ as the difference between the risk score each beneficiary would have generated in MA relative to the risk score she would have generated in FFS, the average (per capita plan-level) MA subsidy is then $\bar{C}(1 + \rho(\delta, \gamma))$ which simplifies to \bar{C} when we assume, counter to the empirical facts we document, that risk scores are fixed properties of individuals and invariant to MA enrollment.

3.2 Planner's Problem

To illustrate how the competitive equilibrium may yield inefficiencies, consider as a benchmark a social planner who is designing an MA alternative to FFS, and whose policy instruments include δ , γ , and the supplemental MA premium p . The planner takes as given the cost, zero price, and reservation utility of the FFS option, though we return to the issue of the social cost of FFS further below.¹⁴ The planner maximizes consumer utility generated by MA plan services, net of the resource cost of providing them:

$$\max_{\delta, \gamma} [v(\delta) + w(\gamma) + \sigma_i - \delta - \gamma] \quad (1)$$

First order conditions with respect to γ and δ yield

$$v'(\delta^*) = 1 \quad (2a)$$

$$w'(\gamma^*) = 1. \quad (2b)$$

¹³A weaker assumption—that on net consumers of different costs may systematically sort to MA, but that such sorting between MA and FFS is compensated as intended by risk adjustment—suffices. However, this alternative formulation significantly complicates the notation and proofs without enhancing the intuitions generated by the model. See an earlier version of this paper, available as [Geruso and Layton \(2015\)](#), for this alternative approach.

¹⁴We set the price of FFS Medicare at zero, as the (small) Part B premiums are paid regardless of the MA/FFS choice. We also take as given the cost and reservation utility of the FFS Medicare option, but if these were free parameters, the socially optimal MA plan could be iteratively determined by first determining the optimal level of FFS provision, \bar{C} .

At the optimal provision of healthcare services and the optimal investment in coding, the marginal consumer utility of γ and δ equal their marginal costs, which is 1 by construction.

Next consider the price p^* that efficiently allocates consumers to the FFS and MA market segments. In an efficient allocation, consumers choose the MA plan if and only if the social surplus generated by MA for them exceeds the social surplus generated by FFS. This condition is

$$v(\delta) + w(\gamma) + \sigma_i - \delta - \gamma > \bar{u} - \bar{C} \quad (3)$$

A consumer chooses MA only if her valuation of MA minus the premium exceeds her reservation utility in the FFS option at its zero price. Thus consumers choose MA if and only if $v(\delta) + w(\gamma) + \sigma_i - p > \bar{u}$. This criterion for a consumer choosing MA matches the efficient allocation condition in (3) if $p = \delta + \gamma - \bar{C}$. Thus the planner sets the MA/FFS price difference equal to the resource cost difference of the MA plan relative to FFS. This is the familiar result that (incremental) prices set equal to (incremental) marginal costs induce efficient allocations.

3.3 Insurer Incentives and Coding in Equilibrium

We next consider an MA insurer who sets $\{\delta, \gamma; p\}$ in a competitive equilibrium. Competition will lead to all insurers offering a contract that maximizes consumer surplus, subject to the zero-profit condition, or else face zero enrollment. Because consumer preferences are identical up to a taste-for-MA component that is uncorrelated with δ and γ and is uncorrelated with costs net of risk adjustment, there is a single MA plan identically offered by all insurers in equilibrium. The zero profit condition here is $p + S = \delta + \gamma$. As described above, healthcare utilization as well as spending on coding technologies can result in higher subsidies because such activities affect reported risk scores, leading to subsidies $S(\delta, \gamma) = \bar{C} \cdot (1 + \rho(\delta, \gamma))$ under the rules of MA. The insurer's problem, where we have substituted for price from the zero profit condition, is then

$$\max_{\delta, \gamma} \left[v(\delta) + w(\gamma) - \left(\delta + \gamma - \bar{C}(1 + \rho(\delta, \gamma)) \right) \right]. \quad (4)$$

and first-order conditions yield:

$$v'(\tilde{\delta}) = 1 - \bar{C} \frac{\partial \rho}{\partial \delta} \quad (5a)$$

$$w'(\tilde{\gamma}) = 1 - \bar{C} \frac{\partial \rho}{\partial \gamma}. \quad (5b)$$

If risk scores were exogenous to δ and γ and fixed at their FFS level, then $\frac{\partial \rho}{\partial \delta} = \frac{\partial \rho}{\partial \gamma} = 0$ and S would amount to a lump sum subsidy. In this case service provision would be set to the socially optimal level in a competitive equilibrium: $v'(\tilde{\delta}) = 1$, $w'(\tilde{\gamma}) = 1$. Additionally, the competitive equilibrium MA premium would be set equal to the premium that efficiently sorts consumers between MA and FFS: $p = \delta + \gamma - \bar{C}$. Efficient plan design would be achieved.

Generally, however, when the subsidy is endogenous to γ and δ , inefficiencies will arise. Given diminishing marginal utility of δ and γ , and assuming that more coding services and more healthcare services lead to higher risk scores, competition under endogenous risk scores induces MA insurers to set the levels of both healthcare spending and coding inefficiently high: $\tilde{\delta} > \delta^*$ and $\tilde{\gamma} > \gamma^*$. This is because on the margin, insurers are rewarded via the subsidy for setting service provision above the level implied by the tradeoff between satisfying consumer preferences and incurring plan costs. The intuition here is the standard public finance result that taxes or subsidies that are responsive to an agent's behaviors induce inefficient behaviors relative to the first best. We show in Appendix Section A.4 that identical distortions arise in the incentives for setting δ and γ in an imperfectly competitive market with endogenous coding.¹⁵ Given the conditions in (5a, 5b), the competitive equilibrium premium will be equal to $\tilde{p} = (\tilde{\delta}_j + \tilde{\gamma}_j) - \bar{C}(1 + \rho(\tilde{\delta}, \tilde{\gamma}))$ because the zero profit condition forces the additional subsidy to be passed through to the consumer as a lower premium. This lower price induces inefficient sorting, tilting consumer choices towards MA.

3.4 Welfare

Although our goal in this paper is not to estimate the welfare impacts of upcoding, modeling these impacts is instructive for understanding the implications of the coding differences we identify. To

¹⁵In Appendix Section A.4, we show that the first order conditions for a monopolist produce the same incentives for setting γ and δ as in the competitive case. Only premium pricing decisions are affected by imperfect competition, with prices equal to marginal costs (net of the subsidy) plus a standard absolute markup term related to the inverse of the price elasticity of demand. The intuition is that if an insurance carrier can pay a chart review contractor \$1.00 to mine diagnosis codes that generate \$1.50 in risk adjustment revenues, they should be expected to do so regardless of market structure.

express welfare, let θ_{MA} and θ_{FFS} denote the fraction of the Medicare market enrolled in the MA and FFS segments, respectively. Let Φ_{MA} and Φ_{FFS} tally the per-enrollee social surplus generated by each option, excepting the idiosyncratic taste component, σ . Enrollment and surplus in the FFS and MA segments are:

$$\theta_{FFS} = F\left(\bar{u} - v(\delta) - w(\gamma) + p(\delta, \gamma)\right) \quad (6a)$$

$$\theta_{MA} = 1 - \theta_{FFS} \quad (6b)$$

$$\Phi_{MA} \equiv v(\delta) + w(\gamma) - \delta - \gamma \quad (6c)$$

$$\Phi_{FFS} \equiv \bar{u} - \bar{C} \quad (6d)$$

Here, θ_{FFS} expresses the fraction of the population for whom idiosyncratic preferences for MA, $\sigma \sim F(\cdot)$, are less than the mean difference in consumer surplus generated by FFS at its zero price relative to the MA alternative at its price $p(\delta, \gamma)$.

Welfare is the social surplus generated for enrollees in each of the MA and FFS market segments minus the distortionary cost of raising public funds to subsidize (both segments of) the market. Using N to denote the total number of Medicare beneficiaries, and using tildes to indicate the competitive equilibrium outcomes with endogenous risk scores, equilibrium social surplus per capita is

$$\tilde{W} = \tilde{\theta}_{MA} \tilde{\Phi}_{MA} + \tilde{\theta}_{FFS} \Phi_{FFS} + \int_{F^{-1}(\tilde{\theta}_{FFS})}^{\infty} \sigma dF(\sigma) - \kappa \cdot \bar{C} \left(\tilde{\theta}_{MA} (1 + \rho(\tilde{\delta}, \tilde{\gamma})) + \tilde{\theta}_{FFS} \right), \quad (7)$$

where the integral term accounts for the variable component of surplus generated by idiosyncratic tastes for MA among those who enroll in MA. The last term captures the distortionary cost of financing Medicare. It is the government's expenditure on FFS plus its expenditure on MA, multiplied by the excess burden of raising public funds, κ . Taking per capita FFS costs, \bar{C} , as given and assuming that the levels of δ and γ chosen by the MA plans generate risk scores that exceed the FFS risk scores, public spending on the Medicare program increases for every consumer choosing MA instead of FFS. Without differential coding, FFS and MA risk scores are the same ($\rho = 0$) and the public funds term would reduce to $\kappa \cdot \bar{C}$, irrespective of the share of beneficiaries choosing MA.

Next consider the welfare loss associated with endogenous coding by comparing the social surplus in (7) to a (possibly infeasible) regime in which risk scores are exogenously determined and

service levels are optimally set. With \tilde{W} defined as above, let W^{Exo} denote the social surplus per capita in a competitive equilibrium in which risk scores are exogenous to plan choices, which we show above replicates the social planner's solution in the same setting. Using stars to indicate plan features (δ^*, γ^*) and market outcomes (θ^*, Φ^*) in the case of first best service levels and exogenously determined subsidies that do not depend on those levels, this difference is

$$\begin{aligned} \tilde{W} - W^{\text{Exo}} = & \underbrace{-\kappa \cdot \bar{C} (\tilde{\theta}_{MA} \cdot \rho(\tilde{\delta}, \tilde{\gamma}))}_{\text{(i) excess burden of additional government spending}} \\ & \underbrace{-(\theta_{MA}^* - \tilde{\theta}_{MA})(\Phi_{MA}^* - \Phi_{FFS}) + \int_{F^{-1}(\theta_{MA}^*)}^{F^{-1}(\tilde{\theta}_{MA})} \sigma dF(\sigma)}_{\text{(ii) inefficient sorting}} \underbrace{-\tilde{\theta}_{MA}(\Phi_{MA}^* - \tilde{\Phi}_{MA})}_{\text{(iii) inefficient contracts}}. \end{aligned} \quad (8)$$

The expression, derived in Appendix A.5, reveals three sources of inefficiency that arise from linking the MA subsidy to risk scores that plans can influence: (i) a subsidy “overpayment” to MA plans that is not balanced by a reduction in FFS spending, thus expanding overall spending on the Medicare program and the consequent public funds cost; (ii) an allocative inefficiency in which consumers sort to the wrong FFS vs MA market segment because the MA prices are distorted; and (iii) a resource use inefficiency in which plans over-invest in services that affect risk scores relative to the value of these plan features to consumers.

Although we are not able to estimate the necessary parameters for assessing the extent of each of the three inefficiencies, our estimation recovers $\rho(\tilde{\delta}, \tilde{\gamma})$, the differential coding intensity in MA relative to FFS. We also alternatively examine various $\rho_j(\tilde{\delta}_j, \tilde{\gamma}_j)$ for subsegments j of MA, such as provider owned plans and non-profits. This parameter is key in quantifying term (i) in Equation (8). Because the base payment \bar{C} and the fraction of the market in MA ($\tilde{\theta}_{MA}$) are quantities that are directly observable, we can calculate term (i) after recovering $\rho(\tilde{\delta}, \tilde{\gamma})$. We do this in Section 8.1. Note that this quantity reflects the difference between actual MA coding and FFS coding, not the difference between actual MA coding and optimal MA coding, $\rho(\delta^*, \gamma^*)$, which too could differ from FFS coding.¹⁶

¹⁶Although we motivate the potential overprovision of services that impact risk scores by appealing to insurer first order conditions, any MA/FFS difference that leads to different risk scores in MA can be interpreted in light of the welfare expression in (8). For example, suppose that physicians were completely non-responsive to insurer incentives to inflate risk scores. Differences in consumer cost sharing or physician practice styles between FFS and MA could nonetheless have the practical effect of generating different risk scores. In this case, term (i) would nonetheless correctly describe the differential excess burden associated with providing Medicare through MA instead of FFS.

Term (ii) is a function of how many consumers choose MA in equilibrium relative to the first best: $\theta_{MA}^* - \tilde{\theta}_{MA}$. In Section 8.2 we combine our estimates of ρ with parameters from the MA literature to calculate how different the size of the MA market would be relative to what we observe if the differential MA subsidy to coding were removed, shedding some light on the size of this distortion. Term (iii) reveals that even if consumers place positive value on the marginal coding services provided by plans (i.e., $v(\tilde{\delta}) - v(\delta^*) > 0$), there is a welfare loss with endogenous risk scores because the incremental valuation of the coding services is less than the incremental social cost ($v(\tilde{\delta}) - v(\delta^*) < \tilde{\delta} - \delta^*$). Insurers don't internalize the full social cost of these services because the subsidy partially compensates them for coding-related activities at a rate $\bar{C} \frac{\partial \rho}{\partial \delta}$.

Because our empirical strategy is not designed to recover consumer preferences over healthcare services, we cannot estimate term (iii). The term nonetheless provides useful intuitions in interpreting our results. For example, it implies that inefficiencies may also arise in the provision of *non-coding* services such as annual wellness visits and lab tests if these have incidental impacts on the probability that a diagnosis is captured. In the controversial case of MA home health risk assessments, even if home visits provide value to enrollees, such valuations are likely to fall below the social cost of provision and would not have been included in plans if insurers were responding only to consumer preferences over healthcare services. Likewise, it is possible in principle that consumers get value out of intensive coding, perhaps because physicians have more information about their conditions and can thus provide better treatment. The model shows that while improved coding may be valued by consumers, profit maximization implies that in equilibrium its value will be exceeded by its (social resource) cost, so the additional coding is still inefficient.

Equation (8) also informs how the government, as an actor, may or may not address the specific inefficiencies caused by the coding incentive. The primary strategy currently used by regulators to address the implicit MA overpayment is to deflate private plan risk scores, by some amount η . If η is set equal to ρ , then the additional cost of public funds terms can be eliminated.¹⁷ However, this does not eliminate welfare losses due to inefficient sorting (term ii), as the new net-of-subsidy MA price still does not accurately reflect the differential cost of FFS vs. MA, or due to inefficient contracts (term iii), as the insurer's marginal incentives to code intensely are not changed by subtracting a fixed term

¹⁷In this case the subsidy to MA plans of the type $(\tilde{\delta}, \tilde{\gamma})$ equals $\kappa \cdot \bar{C} (1 + \rho(\tilde{\delta}, \tilde{\gamma}) - \eta) = \kappa \cdot \bar{C}$ which is the same as the corresponding term in W^{Exo} , implying that the difference in public spending between $\tilde{W} - W^{\text{Exo}}$ goes to zero.

from the subsidy.^{18,19}

Finally, we note that the welfare analysis here is relative to a first best in a setting with exogenously determined subsidies. It assumes away other distortions in the MA market that affect prices and the design of plan services. Although our focus is on the specific distortions generated by the coding incentive, these are just one piece in the broader landscape of efficiency and welfare in the MA program. A complete second best analysis must account for other simultaneous market failures, including positive externalities generated by the MA program. Indeed, a popular argument in favor of MA is that it might create important spillover effects for FFS Medicare. Studies of physician and hospital behavior in response to the growth of managed care suggest the possibility of positive externalities in which the existence of managed care plans lowers costs for all local insurers (Baker, 1997; Glied and Zivin, 2002; Glazer and McGuire, 2002; Frank and Zeckhauser, 2000). Any positive spillovers, such as the role of MA in lowering hospital costs in FFS Medicare (Baicker, Chernew and Robbins, 2013), should be balanced alongside the additional welfare costs of MA discussed here.²⁰ Such terms, dollar-denominated, could be directly added to Equation (8).

3.5 Upcoding, Complete Coding, and Socially Efficient Coding

Motivated by the model, we define upcoding in MA as the difference between the risk score a consumer would receive if she enrolled in an MA plan and the score she would have received had she enrolled in FFS: $\rho_i(\delta, \gamma) \equiv r_{i,MA} - r_{i,FFS}$. It is simply the differential coding intensity between FFS and MA, which maps to the first source of inefficiency documented in Equation (8). It is the parameter required to measure the excess spending (and, therefore the excess burden) associated with a consumer choosing MA in place of FFS.

As an alternative benchmark, one could define upcoding as many physicians do: the difference between a reported risk score and the risk score that would be assigned to an individual if coding were “complete” in the sense that the individual was objectively examined and all conditions were

¹⁸The cost of public funds terms is also largely eliminated in settings such as the ACA Marketplaces where there is no public option and risk adjustment is “budget neutral” (i.e. the overall level of government subsidies via the risk adjustment system is zero), but again in equilibrium net-of-subsidy prices will not accurately reflect costs and insurers will offer contracts with levels of both coding and healthcare services that are too high.

¹⁹Even within Medicare Advantage, if our assumption that the cost of coding and healthcare services is the same across insurers (or, similarly, that consumers’ valuation functions for healthcare and coding services are identical across insurers) were relaxed, insurers would receive differential subsidies that would cause additional price distortions and lead to further inefficient sorting.

²⁰It is also plausible that coding intensity could be inefficiently low in the absence of the risk score subsidy if coding activities are shrouded attributes of plans and so not driven to efficient provision by competitive forces.

recorded. Even setting aside the practical and conceptual difficulties with such a definition,²¹ our model highlights its welfare-irrelevance. A benchmark of complete coding does not consider the social resource costs of the coding. This highlights an important distinction between the economist’s and physician’s view of this phenomenon.

A more useful alternative benchmark would be the difference between the equilibrium level of coding services ($\tilde{\delta}$) and the socially efficient level (δ^*). We cannot observe this, given that our data contain no information on the marginal costs of providing coding-related services, and given that our identifying variation is keyed to recovering coding differences rather than recovering consumer valuations over various healthcare services. We view understanding the socially efficient level of diagnosis coding as an important avenue for future research. In particular, this would be informative as to the size of the third source of inefficiency from Equation (8), inefficient contract design.

4 Identifying Upcoding in Selection Markets

The central difficulty of empirically identifying upcoding arises from selection on risk scores. At the health plan level, average risk scores can differ across plans competing in the same market either because coding differs for identical patients, or because patients with systematically different health conditions select into different plans. Our solution to the identification problem is to focus on market-level, rather than plan-level, reported risk. Whereas the reported risk composition of plans can reflect both coding differences and selection, risk scores calculated at the market level will not be influenced by selection—that is, by how consumers sort themselves across plans within the market. Therefore, changes in risk scores at the market level as consumers shift between plans within the market will identify differences in coding practices between the plans.

To see this, consider how the mean risk score in a county changes as local Medicare beneficiaries shift from FFS to MA. As before, define the risk score an individual would have received in FFS as $r_{i,FFS} = \hat{r}_i$. Define the same person’s risk score had they enrolled in MA as $r_{i,MA} = \hat{r}_i + \bar{\rho} + \epsilon_i$, where $\bar{\rho}$ is the mean coding intensity difference between MA and FFS across all i and where we allow for individual-level heterogeneity in the difference between MA and FFS risk scores as captured by

²¹For example, take the case of determining diabetes via an A1C blood test: If a patient’s *true* A1C level flits back and forth across a clinical threshold for diabetes over the course of a year, does he have diabetes this year? Further, given that a reasonable assumption is that the American Diabetes Association will someday revise its guidance over such thresholds, do we base our objective measure of diabetes today on the current thresholds, or must we be agnostic about the presence of diabetes today, knowing that medical science will someday change the diagnostic criteria?

ϵ_i . Using $\mathbb{1}[MA_i]$ as the indicator function for choosing MA, an individual's realized risk score is then $r_i(\mathbb{1}[MA_i]) = \hat{r}_i + \mathbb{1}[MA_i](\bar{\rho} + \epsilon_i)$. Let $\epsilon(\theta)$ be the average value of ϵ_i for the set of consumers on the MA/FFS margin when the MA enrollment share equals θ . The county-level mean risk score as a function of MA enrollment can thus be written as $\bar{r}(\theta^{MA}) = \bar{r} + \int_0^{\theta^{MA}} (\bar{\rho} + \epsilon(t)) dt$, where \bar{r} expresses the unconditional expectation of \hat{r}_i . The integral measures the mean MA/FFS coding difference among the types choosing MA. In the simple case of no individual heterogeneity in the size of the coding effect, $\bar{r}(\theta^{MA}) = \bar{r} + \bar{\rho}\theta^{MA}$ and the derivative of the county-level risk score with respect to changes in MA share exactly pins down the difference in coding intensity. That is, $\partial\bar{r}/\partial\theta^{MA} = \bar{\rho}$. In the more complex case in which there is arbitrary heterogeneity in ϵ_i , the slope $\partial\bar{r}/\partial\theta^{MA}$ identifies not the mean differential coding intensity across all i , which is $\bar{\rho}$, but rather the coding difference $(\bar{\rho} + \epsilon_i)$ for the marginal consumers generating the change in market share. (See Appendix A.6.)

Figure 1 provides a graphical intuition of this idea for the simple case of a constant additive effect of MA enrollment on risk scores. We depict two market segments that are intended to align with FFS and MA, though the intuitions apply to considering coding differences across MA plans within the MA market segment as well. In the figure, all consumers choose either FFS or MA. The market share of MA increases along the horizontal axis. The MA segment is assumed to be advantageously selected on risk scores, so that the risk score of the marginal enrollee is higher than that of the average enrollee. Thus, the average risk within the MA segment (\bar{r}^{MA}) is lower at lower levels of θ^{MA} .²² The top panel shows three curves: the average risk in FFS (\bar{r}^{FFS}), the average risk in MA (\bar{r}^{MA}), and the average risk of all enrollees in the market (\bar{r}).

In the top panel of Figure 1, we plot the baseline case of no coding differences across plans ($\bar{\rho} = 0$, $\epsilon_i = 0 \forall i$). As long as there is no coding difference between the plans or market segments, the market-level risk (\bar{r}), which is averaged over all enrollees, is constant in θ . This is because reshuffling enrollees across plan options within a market does not affect the market-level distribution of underlying health conditions. Nor does it affect risk scores if the mapping from health to recorded diagnoses does not vary with plan choice (which is by assumption here). In the bottom panel of Figure 1 we add differential coding. For reference, the dashed line in the figure represents the counterfactual average risk that MA enrollees would have been assigned under FFS coding intensity, \bar{r}_{MA}^{FFS} . The key difference

²²Note that this figure does not describe selection on costs net of risk adjustment, but rather selection on risk scores. This is because our goal here is to distinguish between *risk score* differences due to coding and *risk score* differences due to selection. If selection existed only along net costs (and not risk scores), then estimating coding intensity differences would be trivial. One could directly compare the means of risk scores across plans.

in the bottom panel is that if coding intensity differs, market-level risk \bar{r} changes as a function of MA's market share. This is because even if the population distribution of *actual* health conditions is stationary, market-level *reported* risk scores would change as market shares shift between plans with higher and lower coding intensity. As the marginal consumer switches from FFS to MA, she increases θ^{MA} by a small amount and simultaneously increases the average reported risk (\bar{r}) in the market by a small amount (by moving to a plan that assigns her a higher score). Thus the slope $\partial\bar{r}/\partial\theta^{MA}$ identifies $\bar{\rho}$. We estimate this slope in the empirical exercise that follows.

The core intuition of Figure 1 holds if the data generating process involves multiplicative rather than additive effects of plans on an individual's baseline risk.²³ The core intuition of Figure 1 also holds if there is arbitrary consumer heterogeneity in ϵ_i , though in that case, there is no single coding difference to identify. When ϵ_i varies with θ , the slope will also vary with θ . In that case, estimates of $\partial\bar{r}/\partial\theta^{MA}$ are "local," identifying the average coding difference across the set of consumers who are marginal to the variation in MA penetration used in estimation, analogous to the treatment on the treated. Given that during our sample period we observe within-county changes in MA penetration across all empirically relevant penetration ranges (omitting only very high ranges of θ not observed in practice) this local approximation is likely to reflect the average coding difference for the set of beneficiaries enrolled in the MA market during this period.²⁴ Conveniently, this local estimate is thus also the parameter of interest for determining excess public spending.

Finally, although the bottom panel of Figure 1 depicts the empirically relevant case in which the advantageously selected market segment is more intensely coded, the same intuition applies regardless of the presence or pattern of selection. For illustration, in Appendix Figure A2, we depict a case in which the advantageously selected plan codes less intensely, a case where coding differences exist absent any selection, and a case in which selection is both nonlinear and non-monotonic.

²³If the data generating process for MA risk scores were multiplicative as in $r_i^{MA} = \hat{r}_i(1 + \bar{\rho})$, then $\bar{r}(\theta^{MA}) = \bar{r} + \int_0^{\theta^{MA}} (\bar{\rho} \cdot \hat{r}_i(t)) dt$ and $\frac{\partial\bar{r}}{\partial\theta^{MA}} = \bar{\rho} \cdot \hat{r}_i(\theta)$, where $\hat{r}_i(\theta)$ is the FFS risk score of the consumer type on the MA/FFS margin. Thus if $E[\hat{r}_i(\theta)]$ varied with θ and differed from 1.0, our estimates of $\partial\bar{r}/\partial\theta^{MA}$ should be adjusted by dividing by $E[\hat{r}_i(\theta)]$. We provide evidence in Appendix A.6 that county-level means of \hat{r}_i are not strongly correlated with θ , and that $E[\hat{r}_i]$ is very close to one, so that $\partial\bar{r}/\partial\theta^{MA} \approx \bar{\rho}$.

²⁴For small changes in θ , the slope $\frac{\partial\bar{r}}{\partial\theta^{MA}}$ identifies differential coding intensity ($\bar{\rho} + \epsilon_i$) for the marginal type generating the change in market share. For larger, discrete changes in θ , such as those we exploit in estimation within counties over time, the slope we estimate will be $(\bar{\rho} + \epsilon_i)$ averaged over the consumers on the MA/FFS margin in the range of θ s we observe. See Appendix A.6 for a full discussion.

5 Setting and Empirical Framework

5.1 Data

Estimating the slope $\partial \bar{r} / \partial \theta^{MA}$ requires observing market-level risk scores at varying levels of MA penetration. We obtained yearly county-level averages of risk scores and MA enrollment by plan type from CMS for 2006 through 2011.²⁵ MA enrollment is defined as enrollment in any MA plan type, including managed care plans like Health Maintenance Organizations (HMOs) and Preferred Provider Organizations (PPOs), private fee-for-service (PFFS) plans, and employer MA plans. In our main specifications, we consider the Medicare market as divided between the MA and FFS segments and collapse all MA plan types together. We later estimate heterogeneity in coding within MA, across its various plan type components.²⁶ MA penetration (θ^{MA}) is the fraction of all beneficiary-months of a county-year spent in an MA plan. Average risk scores within the MA and FFS market segments are weighted by the fraction of the year each beneficiary was enrolled in the segment.

All analysis of risk scores in the national sample is conducted at the level of market averages, as the regulator does not generally release individual-specific risk adjustment data for MA plans.²⁷ We supplement these county-level aggregates with administrative data on demographics for the universe of Medicare enrollees from the Medicare Master Beneficiary Summary File (MBSF) for 2006-2011. These data allow us to construct county-level averages of the demographic (age and gender) component of risk scores, which we use in a falsification test.²⁸

Table 1 displays summary statistics for the balanced panel of 3,128 counties that make up our analysis sample. The columns compare statistics from the introduction of risk adjustment in 2006 through the last year for which data are available, 2011. These statistics are representative of counties, not individuals, since our unit of analysis is the county-year. The table shows that risk scores, which

²⁵These data come from the CMS Risk Adjustment Processing (RAPS) system. The RAPS dataset includes risk scores for every Medicare enrollee, both those enrolled in MA and those enrolled in FFS. The FFS risk scores are constructed by CMS using diagnoses found in FFS claims data. The MA risk scores are constructed by CMS using diagnoses submitted to the RAPS by individual MA plans. These diagnoses may or may not appear on MA claims data, as some diagnoses are extracted directly from physician notes instead of from claims. Similar data are unavailable before 2006, since diagnosis-based risk scores were not previously generated by the regulator.

²⁶We exclude only enrollees in the Program of All-inclusive Care for the Elderly (PACE) plans.

²⁷CMS has not traditionally provided researchers with individual-level risk scores for MA enrollees (two exceptions are [Brown et al. \(2014\)](#) and [Curto et al. \(2014\)](#)). A strength of our identification strategy, which could easily be applied in other settings like Medicaid Managed Care and Health Insurance Exchanges, is that it does not require individual-level data.

²⁸The regulator's algorithm specifies that the demographic components (r_i^A) and diagnostic components (r_{ij}^{Dx}) of individual risk scores are additively separable, which implies that the county averages are also additively separable:

$$\bar{r} = \frac{1}{N_c} \sum_{i \in I_c} (r_i^A + r_{ij}^{Dx}) = \bar{r}^A + \bar{r}^{Dx}.$$

have an overall market mean of approximately 1.0, are lower within MA than within FFS, implying that MA selects healthier enrollees.²⁹ Table 1 also shows the dramatic increase in MA penetration over our sample period, which comprises one part of our identifying variation.

5.2 Identifying Variation

We exploit the large and geographically heterogeneous increases in MA penetration that followed implementation of the Medicare Modernization Act of 2003. The Act introduced Medicare Part D, which was implemented in 2006 and added a valuable new prescription drug benefit to Medicare. Because Part D was available solely through private insurers and because insurers could combine Part D drug benefits and MA insurance under a single contract, this drug benefit was highly complementary to enrollment in MA. Additionally, MA plans were able to “buy-down” the Part D premium paid by all Part D enrollees. This, along with increases in MA benchmark payments in some counties, led to fast growth in the MA market segment (Gold, 2009). In the top panel of Figure 2, we put this timing in historical context. Following a period of decline, MA penetration doubled nationally between 2005 and 2011. The bottom panel of the figure shows that within-county penetration changes were almost always positive, though the size of these changes varied widely. A map of changes by county, presented in Figure A3, shows that this MA penetration growth was not limited to certain regions or to urban or rural areas.

Our main identification strategy relies on year-to-year variation in penetration within geographic markets to trace the slope of the market average risk curve, $\partial \bar{r} / \partial \theta^{MA}$. The identifying assumption in our difference-in-differences framework is that year-to-year growth in MA enrollment within counties did not track year-to-year variation in the county’s actual population-level health. The assumption is plausible because the incidence of the types of chronic conditions used in risk scoring (such as diabetes and cancer) is unlikely to change sharply year-to-year. In contrast, *reported* risk can change sharply due to coding differences when a large fraction of the local Medicare population moves to MA. In support of the identifying assumption, we show that there is no correlation between within-county changes in θ^{MA} and within-county changes in a variety of demographic, morbidity, and mortality outcomes that could in principle signal health-motivated demand shifts.

²⁹For estimation, we normalize the national average to be exactly 1.0 in each year, so that coefficients can be read as exact percentage changes. The normalization implies that changes in county-level risk scores are identified only relative to yearly national means. The normalization aids interpretation, but has essentially no impact on the coefficients of interest. See Appendix Table A1 for versions of the main results using non-normalized risk scores.

We also exploit an institutional feature of how risk scores are calculated in MA to more narrowly isolate the identifying variation. Under Medicare rules, the risk scores that are assigned to beneficiaries and used as a basis for payment in calendar year t are based on diagnoses derived from service provision in calendar year $t - 1$. This implies, for example, that if an individual moves to MA from FFS during open enrollment in January of a given year, the risk score for her entire first year in MA will be based on diagnoses she received while in FFS during the prior calendar year. Only after the first year of MA enrollment will the risk score of the switcher include diagnoses she received while enrolled with her MA plan. The timing is more complex for newly-eligible Medicare beneficiaries. In order for an MA enrollee to be assigned a diagnosis-based risk score, CMS requires the enrollee to have accumulated a full calendar year of diagnoses. This implies that changes in θ driven by newly-eligible enrollees should show up in reported risk scores with up to a two year lag.³⁰ In all cases, changes in risk scores due to upcoding should not occur in the same year as the identifying shift in enrollment. We test this.

5.3 Econometric Framework

We estimate difference-in-differences models of the form:

$$\bar{r}_{sct} = \gamma_c + \gamma_t + \sum_{\tau \in T} \beta_{\tau} \cdot \theta_{sct}^{MA} + f(X_{sct}) + \epsilon_{sct}, \quad (9)$$

where \bar{r}_{sct} is the average market-level risk in county c of state s at time t , and θ^{MA} denotes MA penetration, which ranges from zero to one. County and year fixed effects are captured by γ_c and γ_t , so that effects β are identified within counties across time. County fixed effects control for any unobserved constant local factors that could simultaneously affect population health and MA enrollment, such as physician practice style differences documented by [Song et al. \(2010\)](#) and [Finkelstein, Gentzkow and Williams \(2016\)](#), as well as differences in medical infrastructure or consumer health behaviors. Year fixed effects are included to capture any changes in the composition of Medicare at the national level. X_{sct} is a vector of time-varying county characteristics described in more detail below. The subscript τ in the summation indicates the timing of the penetration variable, θ , relative to

³⁰Many individuals first enroll in MA soon after their 65th birthday (rather than January 1st), and so will have incomplete diagnosis records even at the start of the second calendar year of MA enrollment. In this interval, enrollees are given a demographics-based risk score that ignores diagnoses. These facts imply that changes in θ due to the choices of newly-eligible beneficiaries should affect reported risk scores with up to a two-year lag. See [Figure A4](#).

the timing of the reported risk score. This specification allows flexibility in identifying the timing of effects. Coefficients β_τ multiply contemporaneous MA penetration ($\tau = t$), leads of MA penetration ($\tau > t$), and lags of MA penetration ($\tau < t$). Contemporaneous and leading β s serve as placebo tests, revealing whether counties were differentially trending in the dependent variable prior to when risk scores could have plausibly been affected by upcoding

The coefficients of interest are β_{t-1} and β_{t-2} because of the institutional feature described above in which risk scores are calculated based on the prior full year’s medical history, so that upcoding could plausibly affect risk scores only after the first year of MA enrollment for prior FFS enrollees and after the second year of MA enrollment for newly-eligible beneficiaries. A positive coefficient on lagged penetration indicates more intensive coding in MA relative to FFS.

6 Results

6.1 Main Results

Table 2 reports our main results. The coefficient of interest is on lagged MA penetration. In column 1, we present estimates of the baseline model controlling for only county and year fixed effects. The difference-in-differences coefficient indicates that the market-level average risk score in a county increases by about 0.07—approximately one standard deviation—as lagged MA penetration increases from 0% to 100%. Because risk scores are scaled to have a mean of one, this implies that an individual’s risk score in MA is about 7% higher than it would have been under fee-for-service (FFS) Medicare. In column 2, we add linear state time trends, and in column 3, we add time-varying controls for county demographics.³¹ Across specifications, the coefficient on lagged MA penetration is stable.³²

An alternative interpretation of these results is that, contrary to our identifying assumption, the estimates reflect changes in underlying health in the local market. Although we cannot rule out this possibility entirely, the coefficient estimates for the contemporaneous MA penetration variable,

³¹These controls consist of 18 variables that capture the fraction of Medicare beneficiaries in the county-year in five-year age bins from 0 to 85 and 85+.

³²In Appendix Table A2, we show that the results are not sensitive to the inclusion of additional time varying county-level controls, including the share of the Medicare population that is dually-eligible for Medicaid, the share of the Medicare population that is under-65, and other county-level indicators of health status, such as SNP enrollment and ESRD prevalence. In Appendix Table A3 we show that the results are not sensitive to trimming off the smallest and largest 1%, 5%, and 10% of counties by Medicare population size.

reported in the first row of Table 2, constitute a kind of placebo test. If there were a contemporaneous correlation between MA penetration changes and changes in risk scores, it would suggest that the health of the population was drifting in a way that was spuriously correlated with the identifying variation. Contrary to this, the placebo coefficients are very close to zero and insignificant across all specifications. Effects appear only with a lag, consistent with the institutions described above.³³

As discussed above, switchers from FFS to MA carry forward their old FFS risk scores for their first MA plan year, but newly-eligible consumers aging into Medicare at 65 and choosing MA may not have diagnosis-based risk scores assigned to them until after two calendar years of MA enrollment. To investigate, in column 4 of Table 2 we include a second lag of θ in the regression. Each coefficient represents an independent effect, so that point estimates in column 4 indicate a cumulative upcoding effect of 8.7% ($=4.1+4.6$) after two years. This is consistent with a data generating process that causes a two year lag in MA-driven diagnoses entering the risk scores for newly-eligible beneficiaries. But it is also consistent with the possibility that even among switchers, for whom effects could begin to be seen after a one year lag, coding intensity differentials ratchet up over the time a beneficiary stays with an MA plan (Kronick and Welch, 2014). This is plausible, as some insurer strategies for increasing coding intensity, such as prepopulating physician notes with past years' diagnoses, require a history of contact with the patient. We cannot distinguish between these phenomenon in these aggregated data. However, in Section 7, we investigate this issue using a smaller individual-level dataset. There we show how coding differences unfold over the first three years of MA enrollment.

To put the size of our main estimate in context, a 6.4% increase in market-level risk (Table 2, column 3) would be associated with 6% of all consumers in a market becoming paraplegic, 11% developing Parkinson's disease, or 39% becoming diabetic. The effects we estimate would be implausibly large if they reflected true (high frequency) changes in underlying population health. However, if the estimates reflect instead differential coding as we claim, then these magnitudes are closely consistent with widely held beliefs about coding in MA. The Government Accountability Office has expressed concerns that coding differences between MA and FFS are in the range of 5% to 7% (Government

³³In principle, we could extend the placebo test of our main regressions by examining leads in addition to the contemporaneous effect. In practice, we are somewhat limited by our short panel, which becomes shorter as more leads or lags are included in the regression. Due to the length of time diagnosis-based risk adjustment has existed in Medicare, the data extend back only to 2006. The most recent data year available to us is 2011. Therefore, including two leads and one lag of penetration restricts our five year panel to just the three years: 2007 to 2009. Nonetheless, we report on an extended set of leads and lags in Appendix Table A4. The table supports the robustness of our findings in Table 2, though sample size and power are reduced in specifications with more leads and lags.

[Accountability Office, 2013](#)). However, as we show next, the mean MA/FFS coding difference masks important heterogeneity not previously considered by regulators.

6.2 Falsification Tests

As further support of the identifying assumption, in Table 3 we conduct a series of falsification tests intended to uncover any correlation between changes in MA penetration and changes in other time-varying county characteristics not plausibly affected by upcoding. Each column in the table replicates specifications from Table 2, but with alternative dependent variables. In columns 1 and 2, the dependent variable is the demographic portion of the risk score. The demographic portion of the risk score is based only on age and gender, which, unlike diagnoses, are not manipulable by the insurer. CMS retrieves demographic data from the Social Security Administration. Both the lagged and contemporaneous coefficients are near zero and insignificant, showing no correlation between MA penetration and the portion of the risk score that is exogenous to insurer and provider actions.³⁴

In columns 3 through 6 of Table 3, we test whether changes in MA penetration are correlated with independent (non-insurer reported) measures of mortality and morbidity. Mortality is independently reported by vital statistics. For morbidity, finding data that is not potentially contaminated by the insurers' coding behavior is challenging. The typical sources of morbidity data are the medical claims reported by insurers. Here we rely on cancer incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, which operates an independent data collection enterprise to determine diagnoses. Cancer data is limited to the subset of counties monitored by SEER, which accounted for 27% of the US population in 2011 and 25% of the population over 65. In columns 3 and 4, the dependent variable is the county \times year mortality rate among residents age 65 and older. In columns 5 and 6, it is the SEER-reported cancer incidence in the county \times year among residents age 65 and older. Across all of the outcomes in Table 3, coefficients on contemporaneous and lagged MA penetration are consistently close to zero. In Table A5 we show that similar results hold when the dependent variables are various measures of the Medicare age structure in the county \times year. Each falsification test supports the assumption that *actual* county population health was not changing in a way that was correlated with our identifying variation.

³⁴An additional implication of the results in Table 3 (also consistent with our identifying assumption) is that conditional on county fixed effects, MA plans were not differentially entering counties in which the population structure was shifting to older ages, which are more generously reimbursed in the risk adjustment formula.

6.3 Heterogeneity and Provider Integration

Because diagnoses originate with providers rather than insurers, insurers face an agency problem regarding coding. Plans that are provider-owned, selectively contract with physician networks, or follow managed care models (i.e., HMOs and PPOs) may have more tools available for influencing provider coding patterns. For example, our conversations with MA insurers and physician groups indicated that vertically integrated plans often pay their physicians (or physician groups) partly or wholly as a function of the risk score that physicians' diagnoses generate. Within large physician groups, leadership may further transmit this incentive to individuals by placing pressure on low-scoring physicians to bring their average risk scores into line with the group. Integration, broadly defined as the strength of the contract between insurers and providers, could therefore influence a plan's capacity to affect coding.

To investigate this possibility, in Table 4 we separate the effects of market share increases among HMO, PPO, and private fee-for-service (PFFS) plans. HMOs may be the most likely to exhibit integration, followed by PPOs. PFFS plans are fundamentally different. During most of our sample period, PFFS plans did not have provider networks. Instead, PFFS plans reimbursed Medicare providers based on procedure codes (not diagnoses) at standard Medicare rates. Thus, PFFS plans had access to only a subset of the tools available to managed care plans to influence diagnoses recorded within the physician's practice. In particular, PFFS insurers could not arrange a contract with providers that directly financially rewarded intensive coding. PFFS plans could, nonetheless, set lower copays for routine and specialist visits than beneficiaries faced under FFS, which may have increased contact with providers. PFFS plans could also utilize home visits and perform chart reviews.

As in the main analysis, the coefficients of interest in Table 4 are on lagged penetration.³⁵ Point estimates in the table show that the strongest coding intensity is associated with managed care plans generally, and HMOs in particular. Risk scores in HMO plans are around 10% higher than they would have been for the same Medicare beneficiaries enrolled in FFS. PPO coding intensity is around 7% higher than FFS. PFFS and employer MA plans, while intensely coded relative to FFS, exhibit relatively smaller effects. Because today, PFFS comprises a very small (<1%) fraction of MA enrollment, estimates of upcoding based on changes in the HMO/PPO shares (row 1 of columns 1 and 2) are

³⁵These regressions also separately control for penetration by the remaining specialized plan types, which served a small share of the Medicare market. These include Cost Plans, Special Needs Plans, and other temporary CMS demonstration plans. Contemporaneous (year t) effects are entered as controls in the table but the coefficients on these are not displayed.

likely to be more informative of typical MA coding intensity differences today. Estimates inclusive of PFFS (as in Table 2) are informative of the overall budgetary impact of MA during our study period.

In the last column of Table 4, we report on a complementary analysis that classifies MA plans according to whether the plan was provider-owned, using data collected by [Frakt, Pizer and Feldman \(2013\)](#). We describe these data in Appendix Section A.8. The analysis uses provider ownership as an alternative definition of insurer-provider integration. These results indicate that provider-owned MA plans display coding intensity that is larger than the overall mean among MA plans. Provider ownership is associated with risk scores that are about 16% higher than in FFS Medicare, while the average among all other MA plans is a 6% coding difference.

The results in Table 4 show that the overall average difference in coding intensity masks significant heterogeneity across plan types.³⁶ This evidence suggests that the costs of aligning physician and insurer incentives may decline significantly with vertical integration. The issue of vertical relationships in healthcare markets is a topic of considerable research interest (e.g., [Gaynor, Rebitzer and Taylor, 2004](#)) and practical importance, but as [Gaynor, Ho and Town \(2015\)](#) describe in their recent review, examination of vertical integration has generally suffered from “a paucity of empirical evidence.” With the caveat that we cannot rule out the possibility that integrated plans produce different risk scores for reasons unrelated to the closeness of the physician who assigns diagnoses and the plan whose payment depends on it, we view these results as the first (even suggestive) evidence that vertical integration facilitates gaming of the regulatory system. Although the coding phenomenon of interest here is a socially inefficient behavior, our findings regarding integration also hint that strong insurer-provider contracts could be important to the success of programs that target financial incentives at the level of insurers or large provider organizations but that are ultimately intended to influence provider behavior. These include, for example, quality bonuses paid to insurers but based on provider-influenced metrics.

Although the internal organization of the MA plan strongly predicts coding intensity, local adoption of electronic health records (EHRs) appears not to play a significant role. We investigated this possibility using data on adoption of EHR by office-based physicians available from the Office of the National Coordinator for Health Information Technology in the Department of Health and Human

³⁶Our results are also likely to mask richer heterogeneity across individual plans with respect to coding intensity. Some plans might even code less intensely than FFS because they have a strategy based on reduced utilization. We observe only the mean overall effect (Table 2) or the mean effects by plan type (Table 4), so our results do not rule out the possibility that some MA plans are less intensely coded than FFS.

Services. The exercise is described in detail in Appendix Section A.9, and the results are displayed in Table A6. Interactions between lagged penetration and an indicator for high EHR adoption by physician offices in the local market yield coefficients very close to zero, though the standard errors do not rule out small effects. We also investigated heterogeneity in coding intensity along for-profit/not-for-profit status of plans but found no significant differences. (See Appendix A.10 and Table A7.)

Finally, in Appendix Table A8, we examine effect heterogeneity along several margins of cross-county differences, including the starting level of MA penetration, the change in MA penetration over the sample period, the change in market concentration over the sample period, and the Medicare population size. Among these characteristics, there is some evidence that the coding impacts of MA expansions are larger in county markets that began the sample period with lower MA penetration, though we lack the statistical power to estimate this heterogeneity precisely. A larger effect in counties with lower MA shares in 2007 could be consistent with favorable (compensated) selection into MA,³⁷ combined with larger upcoding effects for relatively healthier consumers, though the evidence is mixed: We investigate heterogeneity in coding across beneficiaries of different health statuses in our individual-level analysis in the next section.

7 Individual-Level Evidence

We next turn to a smaller, individual-level dataset. In these data, we can exploit the within-person change in insurance status that occurs when 64-year-olds age into Medicare at 65 and choose either FFS or MA. This allows us to (i) demonstrate the robustness of our key empirical results to an entirely different identification strategy, (ii) investigate the margins along which upcoding occurs, and (iii) generate estimates that fully capture any practice-style spillovers into FFS in the longer-run equilibrium.

7.1 Data: Massachusetts All-Payer Claims

We use the 2010-2013 Massachusetts All-Payer Claims Dataset (APCD) to track how reported diagnoses for a person change when the person enrolls in MA. The APCD includes an individual identifier that allows us to follow consumers across years and health plans as they change insurance status.

³⁷Advantageous selection into MA implies that the marginal MA enrollee is healthier in low-penetration markets, all else equal.

These data cover all private insurer claims data, including Medicare Advantage, Medigap, employer, and individual-market commercial insurers. Therefore, we can observe a consumer in her employer plan at age 64 and then again in her private MA plan at age 65.

FFS claims to Medicare are not directly captured as they are exempted from the Massachusetts regulator's reporting requirements. To indirectly identify claims belonging to FFS enrollees, we follow an approach developed by [Wallace and Song \(2016\)](#), and use data from private Medigap plans. For FFS enrollees with supplemental Medigap coverage, Medigap pays some fraction of almost every FFS claim, creating a duplicate record of the information in the FFS claim sent to Medicare in the form of a Medigap claim we can observe.³⁸ Conditional on the FFS enrollee having a Medigap plan, we observe a complete record of all the diagnosis information needed to construct a risk score. To the extent that our sample of observable FFS enrollees is a good proxy for the full FFS population in Massachusetts with respect to changes in coding at age 65, we can estimate the differential change in diagnoses at 65 among MA enrollees relative to FFS enrollees.³⁹

We focus on two groups of consumers in the data: all individuals who join an MA plan within one year of their 65th birthday and all individuals who join a Medigap plan within one year of their 65th birthday. We divide enrollment spells into 6-month blocks and limit the sample to individuals with at least six months of data before and after joining MA or Medigap. These 6-month periods include different calendar months \times years for different individuals. For example, for an individual who enrolled in Medicare in March 2010, period -1 is September 2009 through February 2010, period 0 is March 2010 through August 2010, period 1 is September 2010 through February 2011, and so on. For the pre-Medicare period we include all 6-month periods during which the individual was continuously enrolled in some form of health insurance. For the post-Medicare period, we include all 6-month periods during which the individual was continuously enrolled in either MA or Medigap. Our final sample includes 34,901 Medigap enrollees and 10,337 MA enrollees. The mean number of 6-month periods prior to Medicare enrollment that we observe is 4.6 (just over 2 years), and the mean number of 6-month periods after Medicare enrollment is 4.4. Additional details regarding the sample

³⁸Nationally, about 31% of 65-year-old FFS enrollees have a supplemental Medigap policy. The only claims that Medigap does not pay any part of are hospital readmissions and lab claims (paid in full by FFS). Our analysis assumes these types of claims contain no relevant diagnoses that are not also recorded on another claim for the beneficiary. For hospital readmissions, it is unlikely that the new admission will include relevant diagnoses of a chronic condition that did not appear in a prior admission. Differential treatment of lab claims is irrelevant for the calculation of risk scores because the CMS algorithm that generates HCCs from claims ignores diagnoses recorded on lab claims.

³⁹Note that this requirement is weaker than requiring that *levels* of risk scores are similar between FFS enrollees with and without Medigap.

construction are included in Appendix Section [A.11](#).

We use diagnoses from the claims data to generate risk scores for each individual based on diagnosed conditions during each 6-month period in the individual’s enrollment panel. Risk scores are calculated according to the same Medicare Advantage HCC model regardless of the plan type in which the consumer is enrolled (i.e., employer, individual market, FFS, or MA). These risk scores do not share the lagged property of the scores from the administrative data used in Sections [5](#) and [6](#) as we calculate the scores ourselves based on current-year diagnoses. We normalize these risk scores by dividing by the pre-Medicare enrollment mean of the 6-month risk score.

7.2 Risk Scores across the Age 65 Threshold

To recover the effect of entering MA relative to entering FFS on an individual’s risk score, we estimate the following difference-in-differences regression:

$$r_{imt} = \beta_0 + \beta_1 MA_i + \beta_2 MA_i \times Post_t + \alpha_t + \Gamma_m + \epsilon_{imt}, \quad (10)$$

where r_{imt} represents i ’s risk score during 6-month period t , MA_i is an indicator equal to one in all periods for anyone who will eventually elect to join MA, $Post_t$ is an indicator equal to one for periods of post-Medicare enrollment, α_t represents fixed effects for each 6-month period relative to initial Medicare enrollment, and Γ_m controls for a full set of month \times year of Medicare entry fixed effects (e.g., joined Medicare in June 2012). β_2 is the difference-in-differences coefficient of interest. It measures the differential change in risk scores between the pre- and post-Medicare periods for individuals enrolling in MA vs. individuals enrolling in FFS. We also estimate versions of this regression where we include individual fixed effects or match on pre-enrollment characteristics.

We begin in Figure [3A](#) by plotting the coefficients from an event study version of Equation (10) where we interact MA_i with each of the period fixed effects (α_t) instead of a single $Post$ indicator. This specification makes it simple to assess the existence of differential pre-trends, which here would indicate that people who would eventually choose MA were already on a path to higher risk scores prior to their actual Medicare enrollment. Each plotted coefficient represents the difference in the differences of risk scores of people entering MA vs. FFS in the indicated period relative to the period just before Medicare enrollment (period -1). The dashed vertical line indicates Medicare enrollment

(the start of period 0). The figure shows that during the 36 months prior to Medicare enrollment, the risk scores for the MA and FFS groups were not differentially trending. Post-Medicare enrollment, however, there is a clear divergence, with risk scores for the MA group increasing much more rapidly than risk scores for the FFS group. By the sixth 6-month period (3 years after Medicare enrollment), normalized risk scores for the MA group were higher by 0.1, or about 10% of the pre-period mean, relative to the FFS group. The apparent growth in the MA coding effect from time zero to 36 months is consistent with the ratcheting-up interpretation of results from column 4 of Table 2 (in the national sample and main identification strategy). These showed that effects were larger (8.7%) by the second year following a shift in θ . Figures 3B and 3C present similar event studies where the dependent variable is the number of HCCs and the probability of having any HCC during the 6-month period, respectively. These figures show similar patterns.

Table 5 presents regression estimates in which all 6-month periods are grouped as either pre- or post-Medicare enrollment spells, as in Equation (10). Column 1 presents results without individual fixed effects, while column 2 includes individual fixed effects, which subsume the MA indicator. The negative coefficient on MA_i in the first row of column 1 indicates that during the pre-Medicare periods, people who would eventually select into MA had lower risk scores than people who would eventually select FFS, consistent with previous evidence that MA is advantageously selected (e.g., Curto et al., 2014). The coefficients of interest on $MA_i \times Post_t$ indicate that risk scores for the MA group grew more rapidly in the post-Medicare periods relative to the FFS group: The risk score of an individual enrolling in MA increased by 4.7 to 5.8% more than the risk score of an individual enrolling in FFS between the pre- and post-Medicare periods. This magnitude is consistent with the visual evidence in Figure 3, if one took the mean over the entire post period.

The results are robust to alternative ways of controlling for MA/FFS selection. In columns 3 through 6 of Table 5, we estimate versions of the regression in column 1 in which we match individuals on pre-period observable characteristics: gender, county of residence, pre-Medicare risk scores, and pre-Medicare count of HCCs. For these regressions, we generate propensity scores on combinations of these variables, then weight the difference-in-differences regressions using these scores, dropping observations for which there is no common support. This matching procedure significantly reduces the coefficient that reflects selection: the coefficient on MA_i reduces from -0.112 to -0.028 . But even as the selection estimate is reduced, estimates of the difference-in-differences effect of in-

terest (the effect of MA enrollment on risk scores in the post period) are stable, remaining similar in size to the main specifications in columns 1 and 2. In Appendix Table A9, we estimate versions of Equation (10) that include interactions between $Post_t$ and a full set of fixed effects for an individual's pre-Medicare plan. Effects are identified off of consumers in the same pre-65 employer or individual market plan who make a different MA/FFS choice at 65. In all robustness exercises, the results are consistent with columns 1 through 6 of Table 5.

These results support and complement the findings of our main analysis, though it is important to understand the limitations of the individual-level analysis. Specifically, the analysis here is limited to just the subset of FFS enrollees who enroll in Medigap. It is also limited to individuals who live in Massachusetts. And the nature of the identification exercise here means that these effects are identified for 65- (but not 85-) year-olds. We also note that point estimates derived from individual claims data are likely to somewhat underestimate effects because claims data do not capture all diagnoses submitted by MA plans to the regulator for risk score purposes. In particular, claims data do not reflect diagnoses added via chart review programs.⁴⁰ Our main, national analysis in Section 6 faces none of these limitations. Nonetheless, these individual data have distinct advantages for considering the mechanisms behind the differential coding in MA. They also allow us to observe coding differences in a setting where MA penetration is stable. We turn to each of these issues next.

7.3 Mechanisms

In addition to the estimates of the coding effects, the richer data in the APCD allows us to investigate some of the mechanisms behind the differential coding increases we observe in MA. Of particular interest is who is upcoded: relatively healthy or relatively sick enrollees? Enrollees who, if not for MA, would not have made contact with the medical system in a given period, or enrollees with regular healthcare utilization regardless of the MA/FFS enrollment choice? Understanding such questions is useful in forming future regulatory frameworks that are less susceptible to manipulable diagnosis coding.

In columns 7 through 10 of Table 5, we investigate MA coding effects along the extensive and

⁴⁰A subset of diagnoses typically come from physicians' notes and are often extracted by third parties or insurer in-house chart review programs. These are submitted to CMS but never recorded on the claims themselves. The omission of these additional diagnoses (which one large insurer suggested to us make up about 20% of all submitted diagnoses) would cause these estimates to be smaller than the estimates from Section 6, which are based on the actual risk scores in the administrative data and so include submitted diagnoses not present on claims.

intensive margins. In columns 7 and 8, we replace the dependent variable with an indicator for having at least one HCC in a 6-month period. Individuals in the MA group have a lower probability of having an HCC during the pre-Medicare period, but their probability of having any HCC increases more in the post-Medicare periods relative to the FFS group. Columns 9 and 10 investigate the intensive margin. The dependent variable in these columns is the number of HCCs during the 6-month period, restricted to person-period observations with at least one HCC. Here the results with and without individual fixed effects have different interpretations. Without fixed effects, the results indicate that the average number of HCCs among person-period observations with at least one HCC increases more quickly after Medicare enrollment for the MA group vs. the FFS group. With fixed effects, the results indicate that *within a person* the average number of HCCs during periods with at least one HCC increases more after Medicare enrollment for the MA group vs. the FFS group. These results suggest that the MA coding effect occurs on both the extensive and intensive margins.⁴¹

We explore this issue further in Appendix Table A10, in which we variously restrict the sample to different subsets based on pre-Medicare health status, as reflected by the diagnosed chronic conditions in the pre-Medicare employer plan. These results show that there are important effects of MA on diagnosis coding for both the healthy and the sick and that the coding effects for the sick are larger.⁴²

The (limited) healthcare utilization information in the APCD also allows us to investigate the role of healthcare use in the coding process. Table A11 presents estimates of versions of Equation 10 where we replace the risk score with indicators for any utilization (columns 1 and 2), any inpatient utilization (columns 3 and 4), and any non-inpatient utilization (columns 5 and 6) during a given 6-month period.⁴³ These results provide novel evidence that MA has a larger positive effect on the extensive

⁴¹Potential changes in composition make it difficult to completely separate the intensive margin effects from extensive margin effects. Because the presence of extensive margin effects implies that the composition of the group of people with at least one HCC differs pre- vs. post-Medicare, the difference-in-differences coefficient could reflect this compositional shift. However, we would expect that the marginal individual, for whom MA causes the documentation of a *first* HCC, would be healthier than the inframarginal individual who would have at least one HCC documented with or without MA. This causes the pool of individuals with at least one HCC to be healthier (and have fewer HCCs overall) under MA than if MA had no effect on the extensive margin. This would make the intensive margin coefficients lower bounds for the true intensive margin effects.

⁴²Appendix Table A8 showed larger effects among counties with lower starting MA penetration. Larger effect sizes for the sick in Table A10 suggests that advantageous selection into MA is not the driving force behind the heterogeneity results in Table A8.

⁴³We focus on extensive margin utilization effects because these are the least likely to be impacted by issues with the quality of the claims data in the APCD. In particular, we are concerned that duplicate reporting could bias measures of utilization measured in spending or visits. In contrast, duplicate records do not impact risk scores, as the n^{th} instance of a particular diagnosis code has zero marginal impact on a risk score after that diagnosis has been established once.

margin of healthcare utilization than FFS. At the same time, MA seems to lower the probability of having any inpatient utilization relative to FFS, though this result goes away when individual fixed effects are included. These results suggest that increasing the probability of ever seeing a doctor during a given year may be a mechanism by which MA plans achieve overall higher risk scores.

Table A12 digs further into coding mechanisms by investigating how MA affects risk scores among the set of MA and FFS enrollees who are using at least some healthcare. Specifications in Table A12 estimate versions of Equation (10) over only the 6 month periods (within individuals) for which there is positive healthcare utilization.⁴⁴ We find that even limiting attention to enrollee-periods with non-zero utilization in MA or FFS, the post-Medicare enrollment growth in risk scores is larger in MA relative to FFS. This suggests that MA-induced differences in the probability that a patient has any contact with a medical provider in a given period (see Table A11) are not solely responsible for the differential coding observed in MA.

7.4 Practice Style Spillovers in Equilibrium

It is possible that the presence of MA in a market affects how FFS enrollees in the same market are coded—perhaps because the same physicians treat patients from both regimes. In the context of the model, spillovers that brought FFS coding closer to MA coding would decrease the excess cost of MA, as only the MA/FFS coding difference matters for the public funds term of Equation (8). But such convergence could nonetheless exacerbate the inefficient attention paid to coding, extending it beyond MA plans.

With respect to our estimates, if coding practice spillovers varied as a function of MA penetration, then our market-level estimates in Section 6.1 would not accurately capture the difference between MA scores and counterfactual FFS scores.⁴⁵ The estimates would still estimate the causal effects of MA on county-level risk scores, but the interpretation would change, as the coefficients would be influenced both by MA/FFS coding differences and by any changes to FFS coding that resulted from higher MA penetration. This potential complication arises because the national analysis is identified

⁴⁴This implies that not all person \times period observations are included for each person.

⁴⁵In this case, $\partial \bar{r} / \partial \theta$ would reflect both consumers moving from a lower coding intensity regime (FFS) to a higher coding intensity regime (MA) and any contemporaneous increases in coding intensity in FFS caused by the spread of MA coding practices. Such spillovers would thus lead to the results from our market-level analysis being overestimates of the difference between FFS and MA coding intensity. The MA/FFS coding difference is the relevant parameter for assessing the MA overpayment. Effects of MA on FFS coding behavior would be relevant for assessing the inefficiency of over-investment in coding services (see Section 3).

off of changes in the local MA presence.

The person fixed-effects analysis, however, does not share this property. In the years leading up to our sample period for the Massachusetts analysis, MA plan presence in Massachusetts was remarkably stable: MA penetration in Massachusetts *declined* by an insignificant 0.2 percentage points from 2008 to 2011. This implies that any coding practice spillovers from MA to FFS are likely to have already occurred and that the coding differences we estimate using the person-fixed effects strategy fully captures equilibrium MA vs. FFS coding intensity differences, net of such spillovers. The person fixed-effects results thus represent a test of whether our estimates from Section 6.1 are overestimates of the longer run MA/FFS coding difference due to spillovers of MA coding practices to FFS. Because the estimated coding differences are very similar under the two identification strategies, this test provides evidence—consistent with beliefs and action by regulators—that FFS coding practices are not merely converging to MA coding practices over time.

8 Discussion

8.1 Additional Government Spending

In the terms of Eq (8), the total additional cost of the Medicare program due to the subsidy being endogenous to risk scores is $\bar{C}(N_{MA}\rho)$.⁴⁶ Here we have scaled up from per capita costs to total program costs by replacing the MA share variable θ_{MA} with the count of beneficiaries, N_{MA} . For every beneficiary choosing MA instead of FFS, total Medicare spending increases by $\bar{C}\rho$, the base payment times the coding intensity difference.

This excess spending can be determined by combining three values: the number of MA enrollees (N_{MA}), the average base subsidy amount paid to MA plans (\bar{C}), and the difference between the MA and FFS risk scores (ρ), which from column 3 of Table 2 is 0.064. We illustrate the size of the public spending impact using program parameters from 2014. In 2014, the average benchmark was \$10,140 and 15.7 million beneficiaries were enrolled in an MA plan.⁴⁷ Combining these values suggests that, absent any regulatory action to deflate MA plan risk scores, the additional public spending due to

⁴⁶Our model ignores some sources of difference between FFS costs and MA payments that are unrelated to coding. For example, due to the MA payment floors created by the Benefits Improvement and Protection Act of 2000, \bar{C} in some counties may be significantly larger than the counterfactual cost of enrolling a beneficiary in FFS, even absent coding effects.

⁴⁷Because of MA's bid and rebate system, the model quantity \bar{C} corresponds most closely to a figure slightly less than the benchmark, equal to the bid plus rebate. See [Song, Landrum and Chernew \(2013\)](#) for an overview of how benchmarks map to final payments via the bidding process.

subsidies being endogenous to coding would have been \$10.2 billion or \$649 per MA enrollee.⁴⁸

In fact, in 2010, toward the end of our study period, CMS began deflating MA risk scores by 3.41%, due to concerns about upcoding. In 2014, the deflation was increased to 4.91%. Factoring this adjustment into our calculations shrinks our estimate of 2014 additional public spending to about \$2.4 billion, or \$151 per MA enrollee. One could transform this accounting figure into a welfare loss given an estimate of κ , the excess burden of raising program funds.

We have generally assumed that ρ is constant across consumers or varies in a way that is uncorrelated with MA penetration. As discussed in Section 4, if instead individual-level heterogeneity in ρ were correlated with θ_{MA} , then our main results would capture coding differences only for the individuals marginal to our variation. In practice, these marginal types are likely to be close to the average MA enrollee. This is because the variation in θ_{MA} we exploit in our empirical analysis covers most of the relevant range of MA penetration, as it arises from a period of massive expansion in the MA market segment. Therefore, even if the individual-specific coding differences are systematically different for beneficiaries who choose MA versus FFS, our estimates likely reflect the parameter necessary to calculate the excess public spending.

8.2 Inefficient Sorting

In our model, MA plans can increase the subsidy they receive by over-providing services relative to the first best. This distorts consumer choices away from FFS and toward MA because MA plans pass (at least part of) these increased subsidies through to MA consumers in the form of lower premiums. Although a full analysis of the welfare costs of inefficient sorting between MA and FFS is beyond the scope of this paper, our estimates of the difference between the MA and FFS risk scores allow us to shed some light on the size of this distortion by quantifying how the size of the MA market is affected by the subsidy to more intense coding. This is related to term (ii) in Equation (8).

To estimate this quantity, we consider a counterfactual policy that uniformly deflates the risk-adjusted payments from the regulator to an MA plan to exactly compensate for the mean MA/FFS

⁴⁸This back of the envelope calculation is illustrative but necessarily imprecise. For example, we find some evidence that effects are larger among counties with the smallest MA presence at the start of our sample period and also perhaps larger among smaller counties (although these results are not robust or precisely estimated). If coding intensity in MA indeed differed by population size, then an ideal calibration of the excess public spending due to upcoding would apply estimates that fully incorporated heterogeneity in the effect sizes. Here we lack the statistical power to estimate such heterogeneity and present instead cost figures based on our main estimate.

coding difference we find. Thus plans receive \bar{C} instead of $\bar{C}(1 + \rho)$.⁴⁹ This change in subsidy, $\Delta S = \rho \cdot \bar{C}$, can be combined with demand elasticity estimates from the literature to arrive at simulated changes in MA enrollment if the coding overpayment were removed. Using program parameters that correspond approximately to 2010, the transition year in which CMS began deflating risk scores, we assume a monthly base capitation payment of $\bar{C} = \$800$. Drawing on the 6.4% estimate from Table 2, column 3, the simulated change in monthly payment is \$51 ($= 0.064 \cdot \800).

Most previous studies of MA demand have estimated semi-elasticities with respect to the consumer premium $\left(\epsilon_p \equiv \frac{\partial \theta / \theta}{\partial p}\right)$, where p equals the consumer premium and θ denotes the MA market segment enrollment, as above. Table 6 reports these demand elasticities from the literature. The parameter needed for generating the relevant counterfactuals is the elasticity of demand for the MA market segment with respect to subsidy payments to MA plans, $\left(\epsilon_s \equiv \frac{\partial \theta / \theta}{\partial S}\right)$. We convert plan price semi-elasticities to plan payment semi-elasticities using empirical estimates of the pass-through rate, $\frac{\partial p}{\partial S}$. The pass-through rate expresses how the marginal government payment to MA plans translates into lower premiums or higher rebates for consumers. Theory predicts that under perfect competition and assuming no selection on enrollee net cost, this parameter would equal -1, as competition forces premiums down dollar-for-dollar with the increased subsidy. Unlike in the stylized model of Section 3, we allow here for imperfect competition, which dampens the enrollment effects of upcoding if pass-through are less than 1 in absolute value. Several studies, including Song, Landrum and Chernew (2013), Cabral, Geruso and Mahoney (2017), and Curto et al. (2014), find pass-through rates in MA of about 50%.⁵⁰ We therefore assume 50% pass-through.

The back-of-the-envelope calculations in the third column of Table 6 show that modifying risk adjustment payments in this way would have large negative impacts on MA enrollment for the range of elasticities estimated in the literature. Using the smallest demand elasticity (Cabral, Geruso and Mahoney, 2017) yields a 17% decline in the size of the MA market, while the most elastic estimate (Dunn, 2010) implies a 33% decline in the size of MA under the counterfactual. These estimates of reductions in MA enrollment apply to a complete elimination of the subsidy relative to a counterfactual in which CMS did nothing to account for differential coding intensity in MA. As discussed

⁴⁹In the conclusion, we discuss more nuanced refinements of current risk adjustment policy, with the potential to reduce the distortionary impacts of within-MA coding differences across plans.

⁵⁰A notable exception is Duggan, Starc and Vabson (2016), which finds a point estimate closer to zero. Under zero pass-through, all of the incidence of the coding subsidy would fall on the plan. Contract features (δ, γ) would still be distorted by the coding incentive, but conditional on these distorted contracts, the overpayment due to coding would not cause consumers to sort inefficiently on the MA/FFS margin.

above, at the end of our sample period CMS began deflating risk scores by 3.41%. In the last column of Table 6 we show the enrollment effects of increasing the CMS risk score deflation from 3.41% to the 6.4% coding difference we estimate. The estimates suggest that the additional deflation would result in a decline in MA enrollment of between 8% and 15%—a decline of 2 and 4 percentage points, respectively, based on 2010 enrollment.⁵¹

If, in addition to an all-MA deflation, coding were differentially deflated across plan types to properly account for coding intensity differences within MA uncovered in Table 4, it is likely that the sorting of consumers across plans *within* the MA segment would be dramatically affected. Provider-owned plans currently capture the largest coding subsidies. Leveling payments would imply reducing payments to these plans by an additional 9.2% beyond the all-MA payment reductions (= 15.6 – 6.4, combining estimates from Tables 2 and 4). [Curto et al. \(2014\)](#) estimate demand response at the MA plan level, rather than MA market segment level, and find own-price elasticities around -1, implying this kind of reshuffling within the MA market could be substantial.

Overall, upcoding has the tendency to increase MA enrollment. Relative to the first best, this decreases welfare. However, in the presence of multiple simultaneous market failures in MA, it is possible that the tendency toward over-enrollment in MA due to coding counteracts some other opposing market failure. For example, MA insurers' market power implies markups that raise prices above marginal costs and constrain enrollment. Setting aside the distortions to MA plan benefits discussed in the next section, the enrollment effects of upcoding could thus be welfare-improving in the second best sense of counteracting market power. Of course, this offsetting relationship between “under-enrollment” in MA due to imperfect competition and “over-enrollment” in MA due to the coding subsidy would be purely coincidental. There is no reason a priori to expect that the coding subsidy specifically counteracts MA insurer market power or any of the other important market failures documented in the context of Medicare Advantage, such as inertia ([Sinaiko, Afendulis and Frank, 2013](#)), spillovers between MA and FFS practice styles ([Baicker, Chernew and Robbins, 2013](#)), or the choice salience of non-cash rebates ([Stockley et al., 2014](#)). Further, the coding subsidy reinforces, rather than counteracts, the overpayment to MA plans generated by uncompensated favorable selection into MA ([Brown et al., 2014](#)).

⁵¹Because these implied effects are large, we note that the only parameter from the present study entering into the calculations in Table 6 is the 6.4% mean coding difference, estimated robustly via two distinct research designs and consistent with regulators' policy actions and long held beliefs about coding.

8.3 Contract Distortions

The final component of the welfare decomposition in Equation (8) describes distortions to the MA contract itself. Our data and identifying variation do not allow us to quantify how much the observed MA contracts differ from efficient MA contracts. Nonetheless, anecdotal evidence is consistent with the idea that contract features and insurer activity are distorted in several important ways. First, there is a niche industry in MA of contractors that provide chart review services to MA carriers—searching medical records to add diagnoses that were never translated to claims. Such activity may have little direct benefit to consumers, as both the patient and their physician will often receive no feedback that their claims-listed diagnoses have changed. Public statements from the regulator, CMS, point to another example of distorted contracts in the form of in-home health assessments. These assessments in MA have drawn CMS attention because they appear aimed primarily at boosting risk scores. Such visits are often not associated with follow-up care or even communication with the primary care physician.⁵² Recent criminal and civil actions brought by the US against MA organizations under the False Claims Act also allege significant insurer—and in some cases physician—efforts to illegally increase risk scores using techniques that would have no clear benefits for patients. In terms of legally distorting physician behavior away from what our model would describe as first best, our discussions with physicians and MA insurers indicate that risk scores are now an explicit part of many insurer-provider contracts in MA in order to align coding incentives between the two parties.

We speculate that the coding incentive, along with similar incentives embedded in new pay-for-performance schemes, may lead to a meaningful share of marginal investments and innovations in healthcare shifting towards the collection and processing of risk score (and other payment-focused) data for which the value to the patient is unclear at best. This cost of diagnosis-based risk adjustment must be considered when evaluating the success of these systems and the important role they play in counteracting the distortions arising from selection. Investigation of the full extent of these costs is an important area for future research.

⁵²In its 2015 Advance Notice, CMS noted that home health risk assessments in MA...“are typically conducted by health-care professionals who are contracted by the vendor and are not part of the plan’s contracted provider network, i.e., are not the beneficiaries’ primary care providers.” And, “Therefore, we continue to be concerned that in-home enrollee risk assessments primarily serve as a vehicle for collecting diagnoses for payment rather than serve as an effective vehicle to improve follow-up care and treatment for beneficiaries.” See Appendix Section A.2 for further discussion.

9 Conclusion

The manipulability of the risk adjustment system via diagnosis coding is an issue of significant practical importance, given the large and growing role of risk adjustment in regulated insurance markets. Our results demonstrate wide scope for upcoding in Medicare Advantage, one of the largest risk-adjusted health insurance markets in the US, relative to the fee-for-service option. The estimates imply significant overpayments to private insurers at a cost to the taxpayer, as well as distortions to consumer choices. We also find evidence that coding intensity is increasing in a plan's level of insurer-provider integration. Our model makes clear that even in managed competition settings such as the ACA Marketplaces—in which risk adjustment has no first-order impact on public budgets because a regulator simply enforces transfers from plans with lower average risk scores to plans with higher average risk scores—risk adjustment transfers that are endogenous to coding intensity distort the provision of coding and non-coding services offered by insurers in equilibrium.

Nonetheless, risk adjustment addresses an important problem of asymmetric information in insurance markets. Therefore, in the second best world in which adverse selection is an inherent feature of competitive insurance markets, the optimal payment mechanism may include some kind of risk adjustment despite the costs of and distortions caused by manipulable coding that we document. Our study offers some insight into potential improvements in risk adjustment mechanism design: From the perspective of this paper, the risk adjustment literature focusing on the predictive content of risk scores is pursuing the wrong objective function. [Glazer and McGuire \(2000\)](#) show that to induce efficient health plan benefit design, risk adjustment must focus on generating insurer incentives rather than predicting expected costs. Applied to our findings, this insight suggests that the (second best) optimal payment policy may include coefficients on risk adjusters that account for the susceptibility of each code to differential coding.

In principle, with information on the upcoding susceptibility of various conditions, it would be possible to estimate optimal payment coefficients by minimizing a loss function that includes coding distortions. In practice, of course, the upcoding susceptibility of risk adjusters (especially new risk adjusters) may be difficult to observe. One simple-to-implement improvement over the current system would be coding intensity deflation factors that separately apply to the demographic portions of the risk score originating from administrative data (such as age, sex, and disability status) versus the plan-reported diagnosis portions. Our results suggest an optimal zero deflation of the

administrative portion (see Table 3) and a higher deflation to diagnoses, counter to current practice.

Another potential reform applies to the audit process. Currently, CMS audits submissions of diagnoses from MA plans, but the audits are only tasked with determining whether diagnoses were legally submitted. Given that much of the upcoding we document is likely to be legal rather than fraudulent, audits that focus instead on the question of whether a given diagnosis would have been submitted under FFS could be helpful in assessing the proper deflation factors to combat overpayments. This could be done, for example, by assessing which diagnoses are established by MA plans solely via chart review (an activity that would not occur in FFS) and not captured in any claim. Such audits could help reduce the excess payments in MA, even if they would not address the marginal incentives to overcommit resources to coding.

Even with significant reform, it may not be possible to achieve perfect parity of coding intensity across the Medicare Advantage and FFS market segments or within MA, among its competing plans. In that case, any benefits of the MA program in terms of generating consumer surplus or creating cost-saving externalities within local healthcare markets should be weighed against the additional taxpayer costs and consumer choice distortions generated by a regulatory system in which the parameters determining insurer payment are squishy.

References


- Baicker, Katherine, Michael E. Chernew, and Jacob A. Robbins.** 2013. "The spillover effects of Medicare managed care: Medicare Advantage and hospital utilization." *Journal of Health Economics*, 32(6): 1289 – 1300.
- Baker, Laurence.** 1997. "HMOs and Fee-For-Service Health Care Expenditures: Evidence from Medicare." *Journal of Health Economics*, 16: 453–482.
- Brown, Jason, Mark Duggan, Ilyana Kuziemko, and William Woolston.** 2014. "How does risk selection respond to risk adjustment? Evidence from the Medicare Advantage program." *American Economic Review*, 104(10): 3335–3364.
- Bundorf, M. Kate, Jonathan Levin, and Neale Mahoney.** 2012. "Pricing and Welfare in Health Plan Choice." *American Economic Review*, 102(7): 3214–48.
- Cabral, Marika, Michael Geruso, and Neale Mahoney.** 2017. "Does Privatized Health Insurance Benefit Patients or Producers? Evidence from Medicare Advantage." *American Economic Review*, forthcoming.
- Carey, Colleen.** 2014. "Government Payments and Insurer Benefit Design in Medicare Part D."
- Chetty, Raj, John N. Friedman, and Jonah E. Rockoff.** 2014. "Measuring the Impacts of Teachers I: Evaluating Bias in Teacher Value-Added Estimates." *American Economic Review*, 104(9): 2593–2632.

- Clemens, Jeffrey, and Joshua D Gottlieb.** 2014. "Do Physicians' Financial Incentives Affect Medical Treatment and Patient Health?" The American economic review, 104(4): 1320.
- CMS.** 2010. "Announcement of Calendar Year (CY) 2010 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies." Centers for Medicare and Medicaid Services.
- Curto, Vilsa, Liran Einav, Jonathan Levin, and Jay Bhattacharya.** 2014. "Can Health Insurance Competition Work? Evidence from Medicare Advantage." National Bureau of Economic Research Working Paper 20818.
- Dafny, Leemore S.** 2005. "How Do Hospitals Respond to Price Changes?" American Economic Review, 1525–1547.
- Decarolis, Francesco.** 2015. "Medicare Part D: Are Insurers Gaming the Low Income Subsidy Design?" American Economic Review, 105(4): 1547–80.
- Duflo, Esther, Michael Greenstone, and Nicholas Ryan.** 2013. "Truth-telling by Third-party Auditors and the Response of Polluting Firms: Experimental Evidence from India." The Quarterly Journal of Economics, 128(4): 1499–1545.
- Duggan, Mark, Amanda Starc, and Boris Vabson.** 2016. "Who benefits when the government pays more? Pass-through in the Medicare Advantage program." Journal of Public Economics, 141: 50–67.
- Dunn, Abe.** 2010. "The Value of Coverage in the Medicare Advantage Insurance Market." Journal of Health Economics, 29(6): 839–855.
- Einav, Liran, Amy Finkelstein, and Mark R. Cullen.** 2010. "Estimating Welfare in Insurance Markets Using Variation in Prices." The Quarterly Journal of Economics, 125(3): 877–921.
- Einav, Liran, Amy Finkelstein, Raymond Kluender, and Paul Schrimpf.** 2015. "Beyond statistics: the economic content of risk scores." MIT.
- Einav, Liran, Amy Finkelstein, Stephen P. Ryan, Paul Schrimpf, and Mark R. Cullen.** 2013. "Selection on Moral Hazard in Health Insurance." American Economic Review, 103(1): 178–219.
- Einav, Liran, and Jonathan Levin.** 2014. "Managed Competition in Health Insurance."
- Finkelstein, Amy, Matthew Gentzkow, and Heidi Williams.** 2016. "Sources of geographic variation in health care: Evidence from patient migration." The quarterly journal of economics, 131(4): 1681–1726.
- Fisher, Elliott S, Stephen M Shortell, Sara A Kreindler, Aricca D Van Citters, and Bridget K Larson.** 2012. "A framework for evaluating the formation, implementation, and performance of accountable care organizations." Health Affairs, 31(11): 2368–2378.
- Frakt, Austin B, and Rick Mayes.** 2012. "Beyond capitation: how new payment experiments seek to find the "sweet spot" in amount of risk providers and payers bear." Health Affairs, 31(9): 1951–1958.
- Frakt, Austin B, Steven D Pizer, and Roger Feldman.** 2013. "Plan–Provider Integration, Premiums, and Quality in the Medicare Advantage Market." Health Services Research, 48(6pt1): 1996–2013.
- Frandsen, Brigham, and James B Rebitzer.** 2014. "Structuring Incentives within Accountable Care Organizations." Journal of Law, Economics, and Organization, ewu010.

- Frank, Richard G, and Zeckhauser.** 2000. "Custom-made versus ready-to-wear treatments: Behavioral propensities in physicians' choices." Journal of Health Economics, 26(6): 1101–1127.
- Gaynor, Martin, James B Rebitzer, and Lowell J Taylor.** 2004. "Physician incentives in health maintenance organizations." Journal of Political Economy, 112(4): 915–931.
- Gaynor, M., K. Ho, and R. Town.** 2015. "The Industrial Organization of Health Care Markets." Journal of Economic Literature, 53(2).
- Geruso, Michael.** 2017. "Demand heterogeneity in insurance markets: Implications for equity and efficiency." Quantitative Economics, 8(3): 929–975.
- Geruso, Michael, and Timothy J. Layton.** 2015. "Upcoding: Evidence from Medicare on Squishy Risk Adjustment." NBER Working Paper.
- Geruso, Michael, and Timothy J. Layton.** 2017. "Selection in Health Insurance Markets and Its Policy Remedies." Journal of Economic Perspectives, Forthcoming.
- Glazer, Jacob, and Thomas G McGuire.** 2000. "Optimal risk adjustment in markets with adverse selection: an application to managed care." The American Economic Review, 90(4): 1055–1071.
- Glazer, Jacob, and Thomas G McGuire.** 2002. "Setting health plan premiums to ensure efficient quality in health care: minimum variance optimal risk adjustment." Journal of Public Economics, 84(2): 153–173.
- Glied, Sherry, and Joshua Graff Zivin.** 2002. "How do doctors behave when some (but not all) of their patients are in managed care?" Journal of Health Economics, 21(2): 337–353.
- Gold, Marsha.** 2009. "Medicare's Private Plans: A Report Card On Medicare Advantage." Health Affairs, 28(1): w41–w54.
- Government Accountability Office.** 2013. "Substantial Excess Payments Underscore Need for CMS to Improve Accuracy of Risk Score Adjustments." Accessed on Oct 8, 2013 at <http://www.gao.gov/assets/660/651712.pdf>.
- Griffin, John M., and Dragon Yongjun Tang.** 2011. "Did Credit Rating Agencies Make Unbiased Assumptions on CDOs?" American Economic Review, 101(3): 125–30.
- Grossman, Sanford J., and Oliver D. Hart.** 1986. "The Costs and Benefits of Ownership: A Theory of Vertical and Lateral Integration." Journal of Political Economy, 94(4): 691–719.
- Gruber, Jonathan.** 2017. "Delivering Public Health Insurance through Private Plan Choice in the United States." Journal of Economic Perspectives, 4(4): 3–22.
- Gruber, Jonathan, Phillip Levine, and Douglas Staiger.** 1999. "Abortion legalization and child living circumstances: who is the "marginal child"?" The Quarterly Journal of Economics, 114(1): 263–291.
- Ho, Kate, Joe Hogan, and Fiona Scott Morton.** 2014. "The Impact of Consumer Inattention on Insurer Pricing in the Medicare Part D Program."
- Kolstad, Jonathan T.** 2013. "Information and Quality When Motivation Is Intrinsic: Evidence from Surgeon Report Cards." American Economic Review, 103(7): 2875–2910.
- Kronick, Richard, and W. Pete Welch.** 2014. "Measuring Coding Intensity in the Medicare Advantage Program." Medicare and Medicaid Research Review, 4(2): E1–E19.


- Newhouse, Joseph P, Mary Price, Jie Huang, J Michael McWilliams, and John Hsu.** 2012. "Steps to reduce favorable risk selection in Medicare advantage largely succeeded, boding well for health insurance exchanges." *Health Affairs*, 31(12): 2618–2628.
- Rothschild, Michael, and Joseph Stiglitz.** 1976. "Equilibrium in Competitive Insurance Markets: An Essay on the Economics of Imperfect Information." *The Quarterly Journal of Economics*, 90(4): 629–649.
- Sacarny, Adam.** 2014. "Technological Diffusion Across Hospitals: The Case of a Revenue-Generating Practice." MIT.
- Schulte, Fred.** 2014. "Judgment calls on billing make upcoding prosecutions rare." *The Center for Public Integrity*, May 19, 2014. Available: <http://www.publicintegrity.org/2012/09/15/10835/judgment-calls-billing-make-upcoding-prosecutions-rare> [Last accessed: 15 April 2015].
- Schulte, Fred.** 2015. "More Whistleblowers Say Health Plans Are Gouging Medicare." *National Public Radio*, May 19, 2014. Available: <http://www.npr.org/blogs/health/2015/04/23/401522021/more-whistleblowers-say-health-plans-are-gouging-medicare> [Last accessed: 15 April 2015].
- Sinaiko, Anna D, Christopher C Afendulis, and Richard G Frank.** 2013. "Enrollment in Medicare Advantage Plans in Miami-Dade County Evidence of Status Quo Bias?" *INQUIRY: The Journal of Health Care Organization, Provision, and Financing*, 50(3): 202–215.
- Song, Yunjie, Jonathan Skinner, Julie Bynum, Jason Sutherland, John E Wennberg, and Elliott S Fisher.** 2010. "Regional variations in diagnostic practices." *New England Journal of Medicine*, 363(1): 45–53.
- Song, Zirui, Mary Beth Landrum, and Michael E Chernew.** 2013. "Competitive bidding in Medicare Advantage: Effect of benchmark changes on plan bids." *Journal of health economics*, 32(6): 1301–1312.
- Stockley, Karen, Thomas McGuire, Christopher Afendulis, and Michael E. Chernew.** 2014. "Premium Transparency in the Medicare Advantage Market: Implications for Premiums, Benefits, and Efficiency." *NBER Working Paper*.
- van de Ven, Wynand P. M. M., and Randall P. Ellis.** 2000. "Risk Adjustment in Competitive Health Plan Markets." In *Handbook of Health Economics*. Vol. 1A, , ed. Anthony J. Culyer and Joseph P. Newhouse, 755–845. Elsevier.
- Wallace, Jacob, and Zirui Song.** 2016. "Traditional Medicare versus private insurance: how spending, volume, and price change at age sixty-five."

Figure 1: Identifying Coding Differences in Selection Markets




Note: The figure illustrates how to separate coding intensity differences from selection when true underlying health risk is unobservable. The horizontal axis measures the market share of MA, θ . The vertical axis measures the average risk score. Average risk in FFS is \bar{r}_{FFS} , average risk in MA is \bar{r}_{MA} , and the average risk of all enrollees in the market is \bar{r} . The dashed line in the bottom panel represents the counterfactual average risk that plan k enrollees would have been assigned under plan j 's coding practices, \bar{r}_{MA}^{FFS} . All consumers choose either FFS or MA. MA is assumed to be advantageously selected in both panels. In the bottom panel MA is also assumed to have higher coding intensity. If and only if there are coding differences between MA and FFS, then the slope of the market-level risk curve with respect to marketshare ($\frac{\partial \bar{r}}{\partial \theta}$) will be different from zero.

Figure 2: Identification: Within-County Growth in Medicare Advantage Penetration



Note: The top panel displays national trends in MA penetration, where the unit of observation is the Medicare beneficiary. *Source:* Kaiser Family Foundation, 2013. The bottom panel displays a histogram of within-county changes in penetration from 2006 to 2011 in the main estimation sample. The unit of observation is the county.

Figure 3: Alternative Identification: Diff-in-Diff Event Study at Age 65



Note: The figure plots coefficient estimates from flexible difference-in-differences regressions in which the dependent variable is risk score (Panel A), count of HCCs (Panel B), or an indicator for any HCC (Panel C). Plotted coefficients are estimated from a version of Equation 10 in which MA_i is interacted with each of the period fixed effects, α_t , instead of a single $Post$ indicator in order to assess pre trends and the unfolding of effects over time in the post-Medicare period. The plotted coefficients represent the regression adjusted differences between individuals who will eventually enter MA versus eventually enter FFS, relative to the period just before Medicare enrollment. The horizontal axis is scaled in 6-month periods during the individual's panel of observations. 95% confidence intervals are plotted with dashed lines. Data are from the Massachusetts All-Payer Claims Database. See text for additional details.

Table 1: Summary Statistics

	Analysis Sample: Balanced Panel of Counties, 2006 to 2011				
	2006		2011		Obs
	Mean	Std. Dev.	Mean	Std. Dev.	
MA penetration (all plan types)	7.1%	9.1%	16.2%	12.0%	3128
Risk (HMO/PPO) plans	3.5%	7.3%	10.5%	10.5%	3128
PFFS plans	2.7%	3.2%	2.7%	3.7%	3128
Employer MA plans	0.7%	2.2%	2.8%	4.3%	3128
Other MA plans	0.2%	1.4%	0.0%	0.0%	3128
MA-Part D penetration	5.3%	8.0%	13.1%	10.8%	3128
MA non-Part D penetration	1.8%	3.0%	3.0%	4.0%	3128
Market risk score	1.000	0.079	1.000	0.085	3128
Risk score in TM	1.007	0.082	1.003	0.084	3128
Risk score in MA	0.898	0.171	0.980	0.147	3124
Ages within Medicare					
<65	19.8%	6.3%	17.2%	6.2%	3128
65-69	23.5%	3.4%	23.7%	3.1%	3128
70-74	19.2%	1.9%	20.2%	2.5%	3128
75-79	15.9%	2.1%	15.4%	1.8%	3128
≥80	21.6%	4.4%	23.5%	5.0%	3128

Note: The table reports county-level summary statistics for the first and last year of the main analysis sample. The sample consists of 3,128 counties for which we have a balanced panel of data on Medicare Advantage penetration and risk scores. MA penetration in the first row is equal to the beneficiary-months spent in Medicare Advantage divided by the total number of Medicare months in the county \times year. The market risk score is averaged over all Medicare beneficiaries in the county and normed to 1.00 nationally in each year.

Table 2: Main Results: Impacts of MA Expansion on Market-Level Reported Risk

	Dependent Variable: County-Level Average Risk Score			
	(1)	(2)	(3)	(4)
MA Penetration t (placebo)	0.007 (0.015)	0.001 (0.019)	0.001 (0.019)	0.006 (0.017)
MA Penetration $t-1$	0.069** (0.011)	0.067** (0.012)	0.064** (0.011)	0.041** (0.015)
MA Penetration $t-2$				0.046* (0.022)
Main Effects				
County FE	X	X	X	X
Year FE	X	X	X	X
Additional Controls				
State X Year Trend		X	X	X
County X Year Demographics			X	X
Mean of Dep. Var.	1.00	1.00	1.00	1.00
Observations	15,640	15,640	15,640	12,512

Note: The table reports coefficients from difference-in-differences regressions in which the dependent variable is the average risk score in the market (county). Effects of contemporaneous (t) and lagged ($t - 1$, $t - 2$) Medicare Advantage (MA) penetration are displayed. Because MA risk scores are calculated using diagnosis data from the prior plan year, changes in MA enrollment can plausibly affect reported risk scores via differential coding only with a lag. Thus, contemporaneous penetration acts as a placebo test. Observations are county \times years. The inclusion of an additional lag in column 4 reduces the available panel years and the sample size. All specifications include county and year fixed effects. Column 2 additionally controls for state indicators interacted with a linear time trend. Columns 3 and 4 additionally control for the demographic makeup of the county \times year by including 18 indicator variables capturing the fraction of the population in 5-year age bins from 0 to 85 and >85 . Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table 3: Falsification Tests: Effects on Measures Not Manipulable by Coding

	Dependent Variable, Calculated as County Average:					
	Demographic Portion of Risk Score		Mortality Over 65		Cancer Incidence Over 65	
	(1)	(2)	(3)	(4)	(5)	(6)
MA Penetration t	0.001 (0.002)	0.001 (0.002)	0.001 (0.002)	0.001 (0.002)	0.001 (0.002)	0.001 (0.002)
MA Penetration t-1	0.000 (0.002)	-0.001 (0.002)	0.000 (0.002)	-0.001 (0.002)	0.000 (0.002)	-0.001 (0.002)
Main Effects						
County FE	X	X	X	X	X	X
Year FE	X	X	X	X	X	X
Additional Controls						
State X Year Trend	X	X	X	X	X	X
County X Year Demographics		X		X		X
Mean of Dep. Var.	0.485	0.485	0.048	0.048	0.023	0.023
Observations	15,640	15,640	15,408	15,408	3,050	3,050

Note: The table reports estimates from several falsification exercises in which the dependent variables are not in principle manipulable by coding activity. The coefficients are from difference-in-differences regressions of the same forms as those displayed in Table 2, but in which the dependent variables are changed, as indicated in the column headers. In columns 1 and 2, the dependent variable is the average *demographic* risk score in the county-year, calculated by the authors using data from the Medicare Beneficiary Summary File based on age, gender, and Medicaid status, but *not diagnoses*. In columns 3 and 4, the dependent variable is the mortality rate which is derived using data from the National Center for Health Statistics. In columns 5 and 6, the dependent variable is the cancer incidence rate from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, which tracks cancer rates independently from rates observed in claims data. The smaller sample size in columns 3 and 4 is due to the NCHS suppression of small cells. The smaller sample size in columns 5 and 6 reflects the incomplete geographical coverage of SEER cancer incidence data. Cancer incidence and mortality are both calculated conditional on age ≥ 65 . Observations are county \times years. Controls are as described in Table 2. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table 4: Heterogeneity by Plan Type and by Plan Integration

	Heterogeneity by Plan Type				By Plan Ownership
	(1)	(2)	(3)	(4)	(5)
HMO & PPO Share, t-1	0.089** (0.026)	0.088** (0.026)			
HMO Share, t-1			0.103** (0.028)	0.101** (0.028)	
PPO Share, t-1			0.068* (0.028)	0.068* (0.028)	
PFFS Share, t-1	0.057* (0.025)	0.058* (0.025)	0.057* (0.025)	0.058* (0.025)	
Employer MA Share, t-1	0.041** (0.012)	0.041** (0.012)	0.041** (0.012)	0.041** (0.012)	
Non-Provider-Owned Plans Share, t-1					0.061** (0.011)
Provider-Owned Plans Share, t-1					0.156** (0.031)
Main Effects					
County FE	X	X	X	X	X
Year FE	X	X	X	X	X
Additional Controls					
State X Year Trend	X	X	X	X	X
County X Year Demographics	X	X	X	X	X
Special Need Plans (SNP) Share		X		X	
Observations	15,640	15,640	15,640	15,640	15,640

Note: The table shows coefficients from difference-in-differences regressions in which the dependent variable is the average risk score in the market (county). Effects of lagged ($t - 1$) MA penetration are displayed, disaggregated in columns 1 through 4 by shares of the Medicare market in each category of MA plans (HMO/PPO/PFFS/Employer MA). Share variables are fractions of the full (MA plus FFS) Medicare population. Regressions in these columns additionally control for the corresponding contemporaneous (t) effects and the share and lagged share of all other contract types. In column 5, MA penetration is disaggregated by whether plans were provider-owned, following the definitions constructed by [Frakt, Pizer and Feldman \(2013\)](#) (see Section A.8 for full details). Observations are county \times years. Controls are as described in Table 2. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table 5: Alternative Identification: Coding Differences at Age 65 Threshold, MA vs. FFS

Dependent Variable:	Risk Score						At least 1 HCC		Count of HCCs	
	D-in-D		Matching D-in-D				Extensive Margin		Intensive Margin	
	Full Sample		Full Sample				Full Sample		At least 1 HCC	
Specification:	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
Selected MA	-0.113** (0.007)		-0.116** (0.006)	-0.054** (0.005)	-0.038** (0.005)	-0.028** (0.005)	-0.043** (0.003)		-0.143** (0.014)	
Post-65 X Selected MA	0.058** (0.009)	0.047** (0.007)	0.058** (0.007)	0.054** (0.007)	0.060** (0.007)	0.051** (0.007)	0.033** (0.004)	0.033** (0.003)	0.090** (0.018)	0.071** (0.018)
Person FE		X						X		X
Matching Variables:										
Gender/County			X	X	X	X				
Count of HCCs				X		X				
Risk Score					X	X				
Mean of Dep. Var.	1.00	1.00	1.00	1.00	1.00	1.00	0.52	0.52	1.07	1.07
Observations	319,094	319,094	316,861	314,293	288,407	287,676	319,094	319,094	118,327	118,327

Note: The table shows coefficients from difference-in-differences regressions described by Eq. 10 in which the dependent variables are the risk score (columns 1 through 6), an indicator for having at least one chronic condition (HCC) during the period (columns 8 and 9), and the count of chronic conditions (HCCs) conditional on periods where individuals have at least one HCC (columns 9 and 10). All regressions compare coding outcomes pre- and post-Medicare enrollment among individuals who select MA vs. individuals who select FFS. Data are from the Massachusetts All-Payer Claims Dataset. Pre-Medicare claims are from commercial/employer plans. Post-65 claims are from Medicare Advantage plans for MA enrollees and Medigap plans for FFS enrollees. The sample is restricted to individuals who join FFS or MA within one year of their 65th birthday and who have at least 6 months of continuous coverage before and after their 65th birthday. The unit of observation is the person-by-six month period, where six-month periods are defined relative to the month in which the individual joined Medicare. Columns 2, 8, and 10 include individual fixed effects. Columns 3-6 report coefficients from regressions where the observations are weighted using propensity scores estimated using the indicated matching variables. The coefficient on “Selected MA” should be interpreted as the pre-Medicare enrollment difference in the outcome for individuals who will eventually enroll in an MA plan vs. individuals who will eventually enroll in FFS. The coefficient on “Post-65 X Selected MA” should be interpreted as the differential change in the outcome post- vs. pre-Medicare for individuals who join an MA plan vs. individuals who join FFS. Data are described more thoroughly in Sections 7 and A.11. Standard errors in parentheses are clustered at the person level. * $p < 0.05$, ** $p < 0.01$.

Table 6: Counterfactual: Implied MA Enrollment Effects of Removing Coding Subsidy

Study	Estimated semi-price elasticity of demand	Implied semi-payment elasticity of demand	Implied enrollment effect of removing overpayment due to coding	
			Relative to counterfactual of no CMS coding adjustment (6.4% reduction in payments)	Relative to counterfactual of 3.4% coding deflation by CMS (3% reduction in payments)
Cabral, Geruso, and Mahoney (2014)	-0.0068	0.0034	-17%	-8%
Atherly, Dowd, and Feldman (2003)	-0.0070	0.0035	-18%	-8%
Town and Liu (2003)	-0.0090	0.0045	-23%	-11%
Dunn (2010)	-0.0129	0.0065	-33%	-15%

Note: The table displays back-of-the-envelope calculations for MA market segment enrollment under a counterfactual in which the subsidy to differential coding is removed. A monthly base payment of \$800 is assumed. Price semi-elasticities are taken from the prior literature. Implied semi-payment elasticities of demand have been derived from semi-price elasticities assuming a pass-through rate of 50%. See text for full details.

APPENDIX

A.1 Background on MA Risk-Adjusted Payments

Medicare Advantage (MA) insurance plans are given monthly capitated payments for each enrolled Medicare beneficiary. The levels of these county-specific payments are tied to historical fee-for-service (FFS) Medicare costs in the county. County capitation rates were originally intended to capture the cost of enrolling the “national average beneficiary” in the FFS Medicare program in the county, though Congress has made many ad hoc adjustments over time.

Before 2004, there was relatively minimal risk adjustment of capitation payments in MA, relying primarily on demographics.⁵³ In 2004, CMS began transitioning to risk adjustment based on diagnoses obtained during inpatient hospital stays and outpatient encounters. By 2007, diagnosis-based risk adjustment was fully phased-in. During our study period (2006-2011), risk-adjusted capitation payments were approximately equal to $S_{ijc} = \phi_{jc} \cdot x_{ijc} \Lambda$, where i indexes beneficiaries, j indexes plans, and c indexes counties (markets).

The base payment, ϕ_{jc} , could vary within counties because since 2006 MA plans have been required to submit bids to CMS. These bids are compared to the uniform county benchmark \bar{C}_c . If the bid is below the county benchmark set by the regulator, the plan receives 75% of the difference between the bid and the benchmark, which the plan is required to fold back into its premium and benefits as a “rebate” to beneficiaries.⁵⁴ Importantly for our purposes, this 75% is still paid out by CMS into the MA program. This implies that any estimation of coding subsidies should be based on the capitation payment to plans inclusive of any rebate, suggesting that the county benchmark, \bar{C}_c , is a good approximation for ϕ_{jc} .

A.2 Diagnosis Coding in Practice

Section 2.2 outlines the practices that insurers can use to influence the diagnosis coding of physicians. Here, we expand on that discussion. In Figure A1, we outline the various mechanisms insurers employ to affect diagnosis coding, and in turn risk scoring. Insights in the figure come from investigative reporting by the Center for Public Integrity, statements by CMS, and our own discussions with MA insurers and physician groups. We exclude any mechanisms that involve illegal action on the part of insurers. While fraud is a known problem in MA coding, coding differences can easily arise without any explicitly illegal actions on the part of the insurer.

First, before any patient-provider interaction even occurs, insurers can structure contracts with physician groups such that the payment to the group is a function of the risk-adjusted payment that the insurer itself receives from the regulator. This directly passes through coding incentives to the physician groups. Insurers may also choose to selectively contract with providers who code more aggressively. Additionally, the insurer can influence coding during the medical exam by providing tools to the physician that pre-populate his notes with information on prior-year diagnoses for the patient. Since risk adjustment in many settings, including MA, is based solely on the diagnoses from a single plan year, this increases the probability that diagnoses, once added, are retained indefinitely. Insurers also routinely provide training to the *physician’s* billing staff on how to assign codes to ensure the coding is consistent with the insurer’s financial incentives. Finally, even after claims and codes

⁵³From 2001-2003 inpatient diagnoses were used in risk adjustment, but in order to weaken insurer incentives to send more enrollees to the hospital, CMS only gave these diagnoses a 10% weight in the risk adjustment payment, leaving the other 90% of the payment based on demographics only.

⁵⁴This description is slightly simplified from the true policy. Often MA plans span multiple counties. When they do, the insurer submits a single bid that is based on an enrollment-weighted average of the county benchmarks across all counties in the plan’s service area.

are submitted to the insurer for an encounter, the insurer may automatically or manually review claims, notes, and charts and either add new codes based on physician notes that were not originally translated to the claims or request a change to the coding in claims by the physician’s billing staff. Insurers use various software tools to scan patient medical records for diagnoses that were not recorded in originally submitted claims, but nonetheless met the statutory diagnosis eligibility requirements and can therefore be added as valid codes.

In addition to these interventions with physicians and their staffs, insurers directly incentivize their enrollees to take actions that result in more intensive coding. Insurers may incentivize or require enrollees to complete annual evaluation and management visits or “risk assessments,” which are inexpensive to the insurer, but during which codes can be added that would otherwise have gone undiscovered. Further, if an insurer observes that an enrollee whose expected risk score is high based on medical history has not visited a physician in the current plan year, the insurer can directly intervene by proactively contacting the enrollee or sending a physician or nurse to the enrollee’s home. The visit is necessary in order to code the relevant, reimbursable diagnoses for the current plan year and relatively low cost. There is substantial anecdotal evidence and numerous lawsuits related to such behavior in Medicare Advantage. See, for example, [Schulte \(2015\)](#). And regulators have expressed serious concern that such visits primarily serve to inflate risk scores. In a 2014 statement, CMS noted that home health visits and risk assessments “are typically conducted by healthcare professionals who are contracted by the vendor and are not part of the plan’s contracted provider network, i.e., are not the beneficiaries’ primary care providers.” CMS also noted that there is “little evidence that beneficiaries’ primary care providers actually use the information collected in these assessments or that the care subsequently provided to beneficiaries is substantially changed or improved as a result of the assessments.”

None of these insurer activities take place in FFS because providers under the traditional system are paid directly by the government, and the basis of these payments is procedures, not diagnoses. Under FFS, hospitals are compensated for inpatient visits via the diagnosis-related groups (DRG) payment system, in which inpatient stays are reimbursed partially based on inpatient diagnoses and partially based on procedures. It is nonetheless plausible that overall coding intensity in FFS and MA differs significantly. For one, the set of diagnoses compensated under the inpatient DRG payment system differs from that of the MA HCC payment system. In addition, the majority of FFS claims are established in the outpatient setting, in which physician reimbursement depends on procedures, not diagnoses. In FFS, diagnoses are instead used for the purpose of providing justification for the services for which the providers are requesting reimbursement.

A.3 Competitive Equilibrium with No Endogenous Risk Scores

In Section 3.3 we claim that under our model, the MA plans $\{\delta, \gamma; p\}$ offered in a competitive equilibrium mirror the parameters set by the social planner. Here we show that. Assume that the risk score is exogenous to the healthcare and coding services offered by the plan, so that the MA/FFS coding intensity difference $\rho(\delta, \gamma)$ is zero. Competition will lead to all insurers offering a contract that maximizes consumer surplus, subject to the zero-profit condition, or else face zero enrollment. Because consumer preferences are identical up to a taste-for-MA component that is uncorrelated with δ , γ , and costs net of risk adjustment, there is a single MA plan identically offered by all insurers. The zero profit condition here is $p + S = \delta + \gamma$. The insurer’s problem, where we have substituted for price, is then

$$\max_{\delta, \gamma} [v(\delta) + w(\gamma) - (\delta + \gamma - S)] \quad (11)$$

This produces the following first order conditions:

$$v'(\delta^*) = 1 \quad (12a)$$

$$w'(\gamma^*) = 1 \quad (12b)$$

The levels of δ and γ chosen in equilibrium thus correspond precisely with the optimal levels from the social planner's problem. Further, the zero profit condition imposes that p is equal to the social planner price that optimally allocates consumers to MA and FFS: $p = \delta^* + \gamma^* - \bar{C}$. Thus, under the assumptions of our model, when S is exogenous to healthcare and coding, insurers offer the socially optimal contract.

Under different assumptions (i.e. preference heterogeneity correlated with cost heterogeneity not captured by the risk adjustment payments), insurers would not necessarily offer the socially optimal contract. We chose these assumptions deliberately to focus on the welfare implications of the coding distortions we study in this paper and abstract from other distortions that may also be relevant in health insurance markets but would introduce complexity that would make the coding distortions more difficult to understand.

A.4 Monopolist's Problem with Endogenous Risk Scores

Here we show that endogenous coding distorts the monopolist's choice of coding services, δ , and other healthcare services, γ , in the same way as in the competitive market. Using notation from Section 3.3, the monopolist's problem is:

$$\max_{p, \delta, \gamma} \left[\theta(p, \delta, \gamma) \left(p - \gamma - \delta + \bar{C}(1 + \rho(\delta, \gamma)) \right) \right], \quad (13)$$

where the term on the right expresses per unit profit as price minus costs plus the subsidy that is a function of coding intensity, and θ denotes the fraction of the Medicare market choosing MA. (To better align notation with Section 3, Eq. (13) maximizes profits normalized by the size of the Medicare eligible population in the market.) This produces the following first order conditions:

$$\frac{\partial \theta}{\partial \delta} \left(p - \gamma - \delta + \bar{C}(1 + \rho(\delta, \gamma)) \right) + \theta \left(-1 + \bar{C} \frac{\partial \rho}{\partial \delta} \right) = 0 \quad (14a)$$

$$\frac{\partial \theta}{\partial \gamma} \left(p - \gamma - \delta + \bar{C}(1 + \rho(\delta, \gamma)) \right) + \theta \left(-1 + \bar{C} \frac{\partial \rho}{\partial \gamma} \right) = 0 \quad (14b)$$

$$\frac{\partial \theta}{\partial p} \left(p - \gamma - \delta + \bar{C}(1 + \rho(\delta, \gamma)) \right) + \theta = 0 \quad (14c)$$

From Section 3, consumer utility net of premiums is $v(\delta) + w(\gamma) + \sigma_i - p$, where σ is distributed $F(\cdot)$.

Noting that $\theta(p, \delta, \gamma) = 1 - F(p - v(\delta) - w(\gamma))$ and defining $U \equiv p - v(\delta) - w(\gamma)$, we rewrite

$\frac{\partial \theta}{\partial p}$ as $-\frac{\partial F}{\partial U}$. We similarly rewrite $\frac{\partial \theta}{\partial \delta}$ as $\left(\frac{\partial F}{\partial U} \cdot v'(\delta) \right)$ and $\frac{\partial \theta}{\partial \gamma}$ as $\left(\frac{\partial F}{\partial U} \cdot w'(\gamma) \right)$. This allows us to

simplify the conditions to:

$$v'(\delta) = 1 - \bar{C} \frac{\partial \rho}{\partial \delta} \quad (15a)$$

$$w'(\gamma) = 1 - \bar{C} \frac{\partial \rho}{\partial \gamma} \quad (15b)$$

$$p = \delta + \gamma - \bar{C}(1 + \rho(\delta, \gamma)) + \left(\frac{-\theta}{\partial \theta / \partial p} \right) \quad (15c)$$

The conditions determining the levels of δ and γ are identical to those in the competitive equilibrium. Prices differ from the competitive equilibrium by a standard absolute markup term. The monopolist sets prices equal to (net) marginal costs plus a markup $\left(\frac{-\theta}{\partial \theta / \partial p} \right)$ that is inversely related to the semi-elasticity of demand with respect to price. With infinite elasticity residual demand, the pricing condition simplifies to the competitive equilibrium price.

If contrary to our model's assumptions, the utility function had non-zero cross derivatives with respect to coding services and premiums, so that the marginal consumer utility generated by an insurer's coding activities covaried with the level of premium paid by the consumer, then the equivalence between the competitive market coding intensity and the monopolist coding intensity would no longer hold. In this case, the level of coding services would be a function of the premium prices (which vary with the level of competition).

A.5 Derivation of Expression 8

Welfare is the social surplus generated for enrollees in each of the MA and FFS market segments minus the distortionary cost of raising public funds to subsidize (both segments of) the market. Following the variable definitions from Section 3.4, the competitive equilibrium social surplus per capita for the case of endogenous risk scores that affect plan subsidies is

$$\tilde{W} = \tilde{\theta}_{MA} \tilde{\Phi}_{MA} + \tilde{\theta}_{FFS} \Phi_{FFS} + \int_{F^{-1}(\tilde{\theta}_{FFS})}^{\infty} \sigma dF(\sigma) - \kappa \cdot \bar{C} \left(\tilde{\theta}_{MA} (1 + \rho(\tilde{\delta}, \tilde{\gamma})) + \tilde{\theta}_{FFS} \right). \quad (16)$$

The competitive equilibrium social surplus per capita for the case of risk scores that do affect plan subsidies, and in which first best levels of coding and healthcare services are provided is

$$W^{Exo} = \theta_{MA}^* \Phi_{MA}^* + \theta_{FFS}^* \Phi_{FFS} + \int_{F^{-1}(\theta_{FFS}^*)}^{\infty} \sigma dF(\sigma) - \kappa \cdot \bar{C}. \quad (17)$$

Note that in the case of Expression 17, the excess burden term reduces to $\kappa \cdot \bar{C}$ because MA by construction costs the same as FFS, and so costs don't vary with MA penetration, θ_{MA} . The difference between \tilde{W} and W^{Exo} can be written:

$$\tilde{W} - W^{Exo} = -\kappa \cdot \bar{C} \left(\tilde{\theta}_{MA} (1 + \rho(\tilde{\delta}, \tilde{\gamma})) + \tilde{\theta}_{FFS} \right) + \kappa \cdot \bar{C} \quad (18)$$

$$+ \tilde{\theta}_{MA} \tilde{\Phi}_{MA} + \tilde{\theta}_{FFS} \Phi_{FFS} - \theta_{MA}^* \Phi_{MA}^* - \theta_{FFS}^* \Phi_{FFS} \quad (19)$$

$$+ \int_{F^{-1}(\tilde{\theta}_{FFS})}^{\infty} \sigma dF(\sigma) - \int_{F^{-1}(\theta_{FFS}^*)}^{\infty} \sigma dF(\sigma). \quad (20)$$

which reduces to:

$$\tilde{W} - W^{\text{Exo}} = \underbrace{-\kappa \cdot \bar{C}(\tilde{\theta}_{MA} \cdot \rho(\tilde{\delta}, \tilde{\gamma}))}_{\text{(i) excess burden of additional government spending}} \quad (21)$$

$$\underbrace{-(\theta_{MA}^* - \tilde{\theta}_{MA})(\Phi_{MA}^* - \Phi_{FFS}) + \int_{F^{-1}(\theta_{MA}^*)}^{F^{-1}(\tilde{\theta}_{MA})} \sigma dF(\sigma)}_{\text{(ii) inefficient sorting}} \quad \underbrace{-\tilde{\theta}_{MA}(\Phi_{MA}^* - \tilde{\Phi}_{MA})}_{\text{(iii) inefficient contracts}}. \quad (22)$$

A.6 Identifying Coding Differences Via the Market Average Risk Score Curve

In Section 4 we claim that the slope of the market average risk score with respect to MA penetration identifies a FFS/MA coding difference. Here we provide proofs and extensions. We begin with the case of an additively separable coding effect and then proceed to an alternative data generating process that involves multiplicative effects. For each case, we discuss the implications if individual heterogeneity in differential coding is correlated with θ .

Define the risk score an individual would have received in FFS as $r_i^{\text{FFS}} = \hat{r}_i$. Define the same person's risk score had they enrolled in MA as the sum of this FFS risk score, a mean MA/FFS difference $\bar{\rho}$ and an arbitrary person-level shifter: $r_i^{\text{MA}} = \hat{r}_i + \bar{\rho} + \epsilon_i$. The ϵ_i term is mean zero ($\bar{\rho}$ removes the mean), but can vary arbitrarily to capture individual-level heterogeneity in the tendency to produce a different risk score in MA relative to FFS. Let $\mathbb{1}[MA_i]$ denote an indicator function for i choosing MA. An individual's risk score as a function of MA enrollment is then $r_i(\mathbb{1}[MA_i]) = \hat{r}_i + \mathbb{1}[MA_i](\bar{\rho} + \epsilon_i)$. The county-level mean risk score as a function of MA enrollment is analogously

$$\bar{r}(\theta^{\text{MA}}) = \bar{r} + \int_0^{\theta^{\text{MA}}} (\bar{\rho} + \epsilon(t)) dt, \quad (23)$$

where \bar{r} expresses the unconditional expectation of \hat{r}_i and the integral captures the average MA/FFS coding difference among MA enrollees when the MA share equals θ^{MA} . Here $\epsilon(\theta)$ describes the epsilon of the consumer type that is on the FFS/MA margin at some θ . (Any variation in ϵ_i that is orthogonal to θ will not impact the derivative of interest.) Small changes in θ identify

$$\frac{\partial \bar{r}(\theta^{\text{MA}})}{\partial \theta^{\text{MA}}} = \frac{\partial}{\partial \theta^{\text{MA}}} \int_0^{\theta^{\text{MA}}} (\bar{\rho} + \epsilon(t)) dt = \bar{\rho} + \epsilon(\theta^{\text{MA}}), \quad (24)$$

where the latter equality follows from the Leibniz rule. Thus, the slope of the market average risk score identifies the coding difference for types just indifferent between MA and FFS. If within this group there is heterogeneity in ϵ_i , the slope identifies $\bar{\rho}$ plus the mean of epsilon among these marginal types. We illustrate the idea in Figure A5. The figure shows how the slope of the market average risk curve (\bar{r}) varies when $\bar{\rho}$ is a function of θ . Note that if $\bar{\rho}$ is not a function of θ then the slope of the market average risk curve is constant across all levels of θ and equal to $\bar{\rho}$. If susceptibility to differential coding intensity varies across consumers in a way that is correlated with MA market share, then the market-level average risk curve will be nonlinear, as this curve integrates over the varying ϵ . In the case that ϵ varies in θ , then $\bar{r}(\theta)$ is non-linear, and small changes in θ identify the MA/FFS coding difference ($\bar{\rho} + \epsilon(\theta^{\text{MA}})$) among consumers on the MA/FFS margin. The estimate of the coding effect is exact for types at the margin, but may not be representative for types away from the identifying variation in θ .

Note that because ϵ_i is allowed to be arbitrary, we have made no assumption on the distribution of \hat{r}_i or on the joint distribution of risks and preferences that generate the within-market segment

average risk curves that describe selection ($\bar{r}^{MA}(\theta)$ and $\bar{r}^{FFS}(\theta)$). As we describe in Section 4, this result simplifies to $\partial\bar{r}/\partial\theta^{MA} = \bar{\rho}$ if individual heterogeneity in the tendency to be differentially coded is orthogonal to θ .

These proofs hold for small variations in θ . In practice, we estimate $\partial\bar{r}/\partial\theta^{MA}$ using larger, discrete changes in θ . As discussed above, in this case the slope of the market average risk curve is equal to $\bar{\rho}$ plus the mean of epsilon among the types whose FFS/MA choice is marginal to the empirical variation in θ used to estimate the slope. This can be seen in Figure A5. In the figure, the market average risk curve (the red line) is assumed to be concave (we find some evidence that $\partial^2\bar{r}/\partial\theta^{MA^2} < 0$ in practice). The dashed line indicates the coding intensity difference for the marginal person at the indicated level of θ : $\bar{\rho} + \epsilon(\theta)$. The figure indicates that the slope of the market average risk curve is equal to this coding intensity difference at any given level of θ .

It now seems prudent to ask what is the parameter of interest here, the marginal or the average coding intensity difference. This depends on the question being asked. For example, one might be interested in knowing how much risk scores would increase if MA penetration went from 0% to 100%. In this case, the average coding intensity difference across the entire population (ρ) would be the parameter of interest. On the other hand, one might be interested in knowing how much risk scores would decrease if MA risk scores were equal to FFS risk scores. Here, the average coding intensity difference across the set of individuals enrolled in MA would be the parameter of interest. Note that in the case where heterogeneity in coding intensity is orthogonal to θ , these two parameters are equivalent. However, in the more general case, they may differ. To see this, let us return to Figure A5. In the figure, the dotted line indicates the average coding intensity difference for the set of individuals enrolled in MA for each level of θ . The line is defined on the left y-axis (0% MA market share) by the coding intensity difference for the first individual to enroll in MA. It is defined on the right y-axis (100% MA market share) by the average coding intensity across the entire population, which in this case is equal to 0.07. Now, assume that in reality $\theta = 0.35$ so that 35% of beneficiaries are enrolled in MA. At this level of θ , the market average risk score is 1.04, the marginal coding intensity difference is 0.09, and the average coding difference among the individuals enrolled in MA is 0.11. Unlike the orthogonal heterogeneity case, these values clearly differ. Now, recall that our estimate of the slope of the market average risk curve depends on the range of θ used to empirically estimate the slope. If we observe variation in θ spanning from $\theta = 0$ to $\theta = 0.35$, then we would estimate a slope of $\frac{1.04-1}{0.35-0} = 0.11$, the average coding difference among the individuals enrolled in MA. This is not a coincidence: The estimated slope of the market average risk curve will always approximate the average coding difference among the set of individuals whose MA/FFS choice is marginal to the variation in MA. This is true for any arbitrary heterogeneity in the coding intensity difference.

Finally, we explore the case where plan coding effects multiply individual risk score components, rather than adding to these. Here, the coding factor can similarly be derived from the slope $\partial\bar{r}/\partial\theta^{MA}$. Consider a data generating process in which $r_i^{FFS} = \hat{r}_i$ as above, but $r_i^{MA} = \hat{r}_i(d + \epsilon_i)$, where $d > 1$ would correspond to higher MA coding intensity. Defining $d \equiv 1 + \bar{\rho}$, an individual's risk score as a function of MA enrollment is $r_i(\mathbb{1}[MA_i]) = \hat{r}_i(1 + \mathbb{1}[MA_i](\bar{\rho} + \epsilon_i))$. The county-level mean risk score as a function MA enrollment is

$$\bar{r}(\theta^{MA}) = \bar{r} + \int_0^{\theta^{MA}} \left(\hat{r}(t) \cdot (\bar{\rho} + \epsilon(t)) \right) dt, \quad (25)$$

where \bar{r} expresses the unconditional expectation of \hat{r}_i . Here $\epsilon(\theta)$ describes the epsilon of the consumer type that is on the FFS/MA margin at some θ . (Any variation in ϵ_i that is orthogonal to θ will not

impact the derivative of interest.) Small changes in θ identify

$$\frac{\partial \bar{r}(\theta^{MA})}{\partial \theta^{MA}} = \frac{\partial}{\partial \theta^{MA}} \int_0^{\theta^{MA}} \left(\hat{r}(t) \cdot (\bar{\rho} + \epsilon(t)) \right) dt = \hat{r}(\theta^{MA}) (\bar{\rho} + \epsilon(\theta^{MA})). \quad (26)$$

In this case, the slope of the market average risk score identifies the coding difference for types just indifferent between MA and FFS, multiplied by the mean FFS risk score of these marginal types, $\hat{r}(\theta)$. Again this result simplifies if individual heterogeneity in the tendency to be differentially coded is orthogonal to θ . In that case, $\partial \bar{r} / \partial \theta^{MA} = \hat{r}(\theta^{MA}) \bar{\rho}$. In practice, the FFS risk scores of the marginal types appear to not vary in θ and are very close to 1.0. In a cross-county regression of mean FFS risk scores on MA share of the form $\bar{r}^{FFS} = \alpha + \beta \theta^{MA} + \mu$, we estimate $\alpha = 0.975$ and $\beta = .058$. Thus even over a wide range of θ , there is very little variation in cross-county means of FFS risk scores (corresponding to $E[\hat{r}_i | \theta^{MA}]$ in the model). To put this in context, these parameters imply that $E[\hat{r}_i | \theta^{MA} = 0.00] = 0.98$ while $E[\hat{r}_i | \theta^{MA} = 0.50] = 1.00$. These are small differences. That these averages don't vary systematically with θ suggests that the marginals likewise do not strongly covary with θ . Because in practice, county-level means of \hat{r}_i appear to be very close to one, $\partial \bar{r} / \partial \theta^{MA}$ is approximately $\bar{\rho}$ without additional adjustment.

A.7 Estimates of Selection

Section 6 describes the results of the main analysis in which we regress county-level averages of risk scores on lagged MA penetration in the county to estimate coding differences. For completeness, here we estimate selection on risk scores, using an analogous set of regressions. Under the assumption that MA penetration changes are exogenous to changes in underlying population health conditional on our controls, selection on risk scores can be estimated by regressing either the average risk score within FFS or the average risk score within MA on contemporaneous and lagged penetration. Note that this reveals only compensated selection, not uncompensated selection as estimated in [Brown et al. \(2014\)](#) and [Cabral, Geruso and Mahoney \(2017\)](#).

Table A13 presents the selection results. Coefficients on contemporaneous MA penetration identify pure selection effects. If selection were monotonic (such as in Figure 1), then positive contemporaneous coefficients in both markets would indicate that as penetration increased, the marginal beneficiary choosing MA was high risk relative to the MA average and low risk relative to the FFS average (according to prior-year diagnoses), increasing the average risk score in both pools. In Table A13, estimates for both FFS and MA risk are imprecise, yielding confidence intervals consistent with a broad range of selection effects, including the findings in [Newhouse et al. \(2012\)](#) of advantageous selection into MA of 4 to 9% of the risk score in 2008.

An important component of selection effects may be captured by the lagged penetration coefficient: Research on MA enrollment by [Sinaiko, Afendulis and Frank \(2013\)](#) shows that many of new MA enrollees are age 65, implying that at least some portion of the shift in MA penetration is likely occurring among the newly Medicare-eligible. In Table A13, this would cause a significant fraction of selection effects to be captured by the lagged coefficient, as new MA enrollees aren't assigned diagnosis-based risk scores until their second year. However, interpreting selection effects in Table A13 is difficult because coefficients on lagged MA penetration are affected by: (i) selection on risk score trajectory and (ii) selection on the unobserved contemporaneous risk score for new enrollees who are not assigned a diagnosis-based score until their second year.

It is important to note that unlike these within-market-segment results, the regressions comprising our main analysis, which examine the effect of lagged penetration on *overall* county risk, are unaffected by selection and yield a straightforward identification of pure coding effects.

A.8 Supplemental Analysis on Plan Ownership

In Section 6 we described results that identified heterogeneity in coding practices across plans with different levels of insurer-provider integration. For our results in column (5) of Table 4, we calculated MA penetration separately for provider-owned plans, using data constructed by [Frakt, Pizer and Feldman \(2013\)](#). Here, we describe those data and results in more detail.

[Frakt, Pizer and Feldman \(2013\)](#) gathered data on provider ownership of plans via plan websites and governance documents for plan year 2009. They limited attention to coordinated care MA-Part D plans (e.g. HMOs and PPOs), excluding employer plans, PFFS plans, and MA plans without drug coverage. We apply their integration flag to our data covering years 2006-2011, using publicly available CMS plan crosswalk files to link the 2009 plan IDs across years. The restriction of [Frakt, Pizer and Feldman \(2013\)](#) to exclude non-drug plans from classification and our implicit assumption that physician ownership was constant from 2006 to 2011 could introduce measurement error, which would bias against our finding of a difference in coding between plans classified as provider-owned and not.

A.9 The Role of Electronic Health Record (EHR) Adoption

Regressions in Table A6 analyze the extent of coding intensity differences across markets classified by differences in the local adoption of electronic health records (EHRs). Here we describe the data used to classify local markets by EHR adoption.

CMS, in cooperation with the Office of the National Coordinator for Health Information Technology, has collected data on meaningful use of EHR systems within physician office settings at the county level. Since 2011, physician offices serving Medicare patients have been incentivized with financial bonuses to report on meaningful EHR use to CMS. We use reports of EHR use during the first year of the incentive program (2011) as a proxy for the existing local EHR infrastructure during our sample period (2006-2011). Within each county, we normalize the count of physicians reporting office EHR adoption by the county Medicare population. Then we define an indicator for high EHR adoption by splitting this metric at the median. Interaction terms in Table A6 between lagged penetration and this indicator for high EHR adoption yield coefficients very close to zero.

A.10 Heterogeneity by For-Profit Status

We classified HMO and PPO plans into three mutually exclusive categories by first partitioning plans into a group including national and large regional carriers and a second group capturing smaller, local organizations. The group of national and large regional plans included, for example, plans offered by Aetna, United Health Group, Blue Cross Blue Shield, and Kaiser. These made up about two-thirds of the enrollee-years in our sample. Smaller organizations included, for example, the Rochester Area Health Maintenance Organization and Puget Sound Health Partners, Inc. We further divided the national and large regional MA carriers by their for-profit/not-for-profit status.

To investigate possible heterogeneity in coding intensity across plans of different for-profit statuses, we generated separate MA market share variables measuring the for-profit and not-for-profit plans and included these as separate regressors in a regression that also included the overall MA share. Table A7 presents the results. Because “main effects” for overall MA penetration are included in each regression, the coefficients on the for-profit and not-for-profit share variables can be interpreted as interaction terms that measure the difference in coding intensity for the indicated type of MA plan, relative to the excluded plan category. Column 1 compares for-profits to an excluded group comprised of not-for-profits and local plans. Column 2 compares not-for-profits to an excluded group comprised of for-profits and local plans. Column 3 estimates separate coefficients for for-profits and

not-for-profits relative to local plans.


The table shows no evidence of differential coding intensity across profit status, or across local versus regional and national plans. Note that while the standard errors on the interaction terms are large enough to potentially mask some heterogeneity, the point estimates for the effect of overall MA penetration are very stable across the additions of profit status controls in columns 1 through 3 (0.063, 0.064, and 0.062). These can be compared to the main coefficient estimate of 0.064 from Table 2.

A.11 Data Notes: Massachusetts All-Payer Claim

Here we provide some additional notes on the data described in Section 7.1 of the paper:

- The Massachusetts All-Payer Claims Dataset (APCD) includes records for 2009 through 2013. We exclude 2009 due to irregularities in the data.
- We drop any individual who is enrolled in both MA *and* Medigap post-Medicare enrollment, either contemporaneously or at different points in time so that our MA and Medigap groups are mutually exclusive. For each individual, we construct a panel of health insurance enrollment at the level of the 6-month period relative to the month in which the individual enrolled in Medicare.
- In sample construction, for the pre-Medicare period we include all 6-month periods during which the individual was continuously enrolled in some form of health insurance except for 6-month periods prior to a gap in coverage. For the post-Medicare period, we include all 6-month periods during which the individual was continuously enrolled in either MA or Medigap except for 6-month periods after a gap in coverage.
- We assume that the set of Medigap FFS enrollees we observe is a good proxy for the full FFS population in Massachusetts with respect to changes in coding at age 65. This requirement is weaker than requiring that levels of risk scores are similar between FFS enrollees with and without Medigap. FFS enrollees with Medigap and FFS enrollees without Medigap are unlikely to experience different *changes* in coding upon enrollment in Medicare. This is because Medigap plans, unlike MA plans, solely reimburse cost-sharing for services and do not engage in care management or steer patients to a particular set of providers. Nonetheless, a mechanism by which Medigap could influence coding in principle is by increasing an enrollee's utilization of health care (via a demand response to net price). This could lead to more provider-patient encounters during which codes could be obtained. Though we expect such effects are ignorably small, such a phenomenon would imply our estimates of FFS-MA coding differences below are biased toward zero: This type of demand response to Medigap would imply that the increase in FFS risk scores at age 65 in our sample overstates the average change in risk scores in FFS overall. This implies that our estimates of the differential change in coding in MA relative to FFS would be a lower bound of the true differential change.


Figure A1: How Risk Scores are Influenced by Insurers




Note: The flowchart illustrates how diagnosis codes originate and how insurers can influence the process that generates them. Insurer actions are towards the left of the figure in blue boxes. Provider actions, including the actions of the provider's billing and coding staff, are towards the right in black boxes. Actions that can immediately result in generation of a code are represented by rhombuses.

Figure A2: Identifying Coding Differences in Selection Markets: Alternative Forms of Selection


(A) Advantageously Selected Plan Codes More Intensely




(B) Advantageously Selected Plan Codes Less Intensely



(C) No Selection and Differential Coding Intensity




(D) Selection is Nonlinear and Non-monotonic




Note: This figure demonstrates how to separate coding differences from selection when true underlying risk is unobservable. The horizontal axis measures the market share of segment k , θ^k . The vertical axis measures the average risk score: Average risk in j is \bar{r}_j , average risk in k is \bar{r}_k , and the average risk of all enrolees in the market is \bar{r} . The dashed line in the figure represents the counterfactual average risk that segment k enrolees would have been assigned under segment j coding practices, \bar{r}_k^j . All consumers choose either plan j or plan k . If and only if there are coding differences between j and k , then the slope of the market-level risk curve with respect to marketshare ($\frac{\partial \bar{r}}{\partial \theta^k}$) will be different from zero.

Figure A3: Geography of Growth in Medicare Advantage, 2006 to 2011




Note: Map shows changes in MA penetration by county between the beginning and the end of our sample period, 2006 to 2011. Counties are binned and color-coded according to their quartile of changes in penetration. Darker regions indicate larger MA growth.

Figure A4: Identification: Coding Effects Plausibly Observed Only with a Lag in Medicare



Note: The diagram highlights the timing of changes in market-level average risk scores (\bar{r}) in response to a change in MA penetration (θ^{MA}). For the first year in either the MA or FFS market segment, switchers carry forward risk scores based on their diagnoses from the previous year in the other segment. For the newly eligible beneficiaries (those turning 65), demographic risk scores are assigned until there is a full calendar year of enrollment and diagnosis information. Therefore, effects on risk scores should not be apparent until year $t + 1$ when the net penetration change is due to switchers and should not be apparent until year $t + 2$ when the net penetration change is due to new Medicare enrollees.

Figure A5: Identification when $\rho + \epsilon$ Varies with θ



Note: Figure shows how the slope of the market average risk curve (\bar{r}) varies when ρ is a function of θ . If susceptibility to differential coding intensity varies across consumers in a way that is correlated with MA market share, then the market-level average risk curve will be nonlinear, and small changes in θ identify the coding intensity difference among consumers on the FFS/MA margin. Here we assume $\rho + \epsilon(\theta) = 0.14 - 0.14\theta$ and plot $\bar{r}(\theta)$ for illustration.

Table A1: Results with Non-Normalized Risk Scores

	Dependent Variable: County-Level Average Risk Score					
	Normalized Dependent Variable (Main Specification)			Non-Normalized Dependent Variable		
	(1)	(2)	(3)	(4)	(5)	(6)
MA Penetration t (placebo)	0.007 (0.015)	0.001 (0.019)	0.001 (0.019)	0.016 (0.016)	0.004 (0.020)	0.004 (0.020)
MA Penetration $t-1$	0.069** (0.011)	0.067** (0.012)	0.064** (0.011)	0.070** (0.011)	0.068** (0.012)	0.066** (0.012)
Main Effects						
County FE	X	X	X	X	X	X
Year FE	X	X	X	X	X	X
Additional Controls						
State X Year Trend		X	X		X	X
County X Year Demographics			X			X
Mean of Dep. Var.	1.00	1.00	1.00	1.03	1.03	1.03
Observations	15,640	15,640	15,640	15,640	15,640	15,640

Note: The table reports coefficients from difference-in-differences regressions in which the dependent variable is the average risk score in the market (county). Effects of contemporaneous (t) and lagged ($t - 1$) Medicare Advantage (MA) penetration are displayed. Columns 1 through 3 repeat specifications in Table 2 for comparison. Columns 4 through 6 use a non-normalized version of the risk score as the dependent variable, rather than normalizing so that the national average is exactly 1.0 in each year. Additional controls are as described in Table 2. Observations are county \times years. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table A2: Robustness to Additional Time Varying County Controls

	Dependent Variable: County-Level Average Risk Score								
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
MA Penetration t (placebo)	0.001 (0.019)	-0.004 (0.019)	0.001 (0.018)	-0.004 (0.019)	0.009 (0.034)	0.001 (0.019)	0.002 (0.021)	0.001 (0.019)	-0.008 (0.039)
MA Penetration $t-1$	0.064** (0.011)	0.064** (0.011)	0.062** (0.012)	0.061** (0.011)	0.077** (0.022)	0.064** (0.011)	0.067** (0.011)	0.063** (0.011)	0.082** (0.022)
Main Controls									
County FE	X	X	X	X	X	X	X	X	X
Year FE	X	X	X	X	X	X	X	X	X
State X Year Trend	X	X	X	X	X	X	X	X	X
County X Year Demographics	X	X	X	X	X	X	X	X	X
Extended Controls (county-by-year)									
Medicare Enrollees		X							X
ln(Medicare Enrollees)			X						X
Share Dual Eligible				X					X
Share Enrolled in Employer MA					X				X
Share <65 (Newly Disabled, Proxy)						X			X
Fraction FFS ESRD							X		X
Share Enrolled in SNP Plans								X	X
Observations	15,640	15,640	15,640	15,640	15,640	15,640	15,640	15,640	15,640

Note: The table reports coefficients from difference-in-differences regressions in which the dependent variable is the average risk score in the market (county). Effects of contemporaneous (t) and lagged ($t - 1$) Medicare Advantage (MA) penetration are displayed. Columns add time varying county-level controls as indicated. Column 6 controls for the share of Medicare enrollees who are under age 65 in the county-year to proxy for changes in county-level prevalence of disability-eligible Medicare beneficiaries. Column 7 controls for the fraction of the FFS population with end-stage renal disease. Main controls are as described in Table 2. Observations are county \times years. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table A3: Results with Weighting and Trimming

Panel A: Weighting by Ln(County Medicare Population)			
	(1)	(2)	(3)
MA Penetration t-1	0.068** (0.009)	0.063** (0.010)	0.060** (0.010)
Observations	15,640	15,640	15,640
Panel B: Dropping Smallest Counties, by Medicare Population Size			
	Trimming < 1 percentile (4)	Trimming < 5 percentile (5)	Trimming < 10 percentile (6)
MA Penetration t-1	0.065** (0.010)	0.060** (0.009)	0.059** (0.009)
Observations	15,480	14,855	14,075
Panel C: Dropping Largest and Smallest Counties, by Medicare Population Size			
	Trimming < 1 & >99 percentile (7)	Trimming < 5 & >95 percentile (8)	Trimming < 10 & >90 percentile (9)
MA Penetration t-1	0.067** (0.010)	0.065** (0.010)	0.064** (0.010)
Observations	15,320	14,070	12,510
Main Effects			
County FE	X	X	X
Year FE	X	X	X
Additional Controls			
State X Year Trend		X	X
County X Year Demographics			X

Note: The table reports coefficients from difference-in-differences regressions in which the dependent variable is the average risk score in the market (county). Effects of lagged Medicare Advantage (MA) penetration are displayed. Contemporaneous effects are included in regressions but suppressed for readability. Panel A weights the regression by the natural log of the size of the county Medicare population. Panel B drops the smallest 1%, 5%, or 10% of counties, by Medicare population size. Panel C drops the smallest and largest 1%, 5%, or 10% of counties, by Medicare population size. Controls are as described in Table 2. Observations are county \times years. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table A4: Extended Placebo Tests: Effects of Contemporaneous Penetration and Leads

	Dependent Variable: County-Level Average Risk Score								
	available panel years:	2007-2011	2007-2010	2007-2009	2008-2011	2008-2010	2008-2009	2009-2011	2009-2010
		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
MA Penetration t+2 (placebo)				0.044 (0.023)			0.030 (0.036)		
MA Penetration t+1 (placebo)			0.017 (0.025)	0.032 (0.056)		-0.005 (0.015)	-0.019 (0.042)		-0.004 (0.034)
MA Penetration t (placebo)	0.001 (0.019)	-0.021 (0.028)	-0.064 (0.071)	0.006 (0.017)	0.003 (0.025)	-0.025 (0.091)	0.011 (0.016)	0.014 (0.043)	
MA Penetration t-1	0.064** (0.011)	0.076** (0.018)	0.084** (0.022)	0.041** (0.015)	0.038 (0.022)	0.025 (0.038)	0.037 (0.032)	0.052 (0.090)	
MA Penetration t-2				0.046* (0.022)	0.054* (0.024)	0.048 (0.041)	0.052 (0.031)	0.100 (0.061)	
MA Penetration t-3							0.023 (0.024)	-0.033 (0.039)	
Main Effects									
County FE	X	X	X	X	X	X	X	X	X
Year FE	X	X	X	X	X	X	X	X	X
Additional Controls									
State X Year Trend	X	X	X	X	X	X	X	X	X
County X Year Demographics	X	X	X	X	X	X	X	X	X
Observations	15,640	12,512	9,384	12,512	9,384	6,256	9,384	6,256	

Note: The table shows coefficients from difference-in-differences regressions in which the dependent variable is the average risk score in the market (county). Effects of future ($t + 2$, $t + 1$), contemporaneous (t), and lagged ($t - 1$, $t - 2$, $t - 3$) Medicare Advantage (MA) penetration are displayed. Because MA risk scores are calculated using diagnosis data from the prior plan year, changes in MA enrollment can plausibly affect reported risk scores via differential coding only with a lag. See Figure A4 for details of this timing. Contemporaneous penetration and leads of penetration serve as placebos that allow for tests for pre-trends within the county. The data include penetration from 2006 through 2011 and market risk from 2007 through 2011. The inclusion of leads and lags determines the available panel years, listed in the header for each column. Observations are county \times years. Controls are as described in Table 2. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table A5: Falsification Test: Effects on Medicare Age Distribution

	Dependent Variable:		Dependent Variable:			
	Fraction ≥ 65	Indicator for Age Bin, Conditional on ≥ 65				
		(1)	65-69 (2)	70-74 (3)	75-79 (4)	80-84 (5)
MA Penetration t	0.003 (0.004)	0.002 (0.007)	0.008 (0.007)	-0.004 (0.006)	-0.001 (0.006)	-0.006 (0.003)
MA Penetration t-1	-0.004 (0.004)	-0.006 (0.006)	0.019** (0.006)	-0.006 (0.007)	-0.003 (0.006)	-0.004 (0.004)
Main Effects						
County FE	X	X	X	X	X	X
Year FE	X	X	X	X	X	X
Additional Controls						
State X Year Trend	X	X	X	X	X	X
County X Year Demographics						
Observations	15,640	15,640	15,640	15,640	15,640	15,640

Note: The table shows coefficients from difference-in-differences regressions in which the dependent variables are indicators for age ranges. The dependent variable in column 1 is the fraction of the Medicare population with age ≥ 65 . The dependent variables in columns 2 through 6 are the fractions of the Medicare population in the indicated age bins, conditional on age ≥ 65 . Data on the Medicare age distribution come from the Medicare Beneficiary Summary File. Observations are county \times years. Controls are as described in Table 2. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table A6: No Coding Interaction with Electronic Health Records

	Dependent Variable: County-Level Average Risk Score		
	(1)	(2)	(3)
MA Penetration t-1	0.069** (0.016)	0.069** (0.017)	0.066** (0.016)
High EHR X MA Penetration t-1	-0.001 (0.018)	-0.004 (0.017)	-0.005 (0.017)
Main Effects			
County FE	X	X	X
Year FE	X	X	X
Additional Controls			
State X Year Trend		X	X
County X Year Demographics			X
Observations	15,640	15,640	15,640

Note: The table shows coefficients from difference-in-differences regressions in which the dependent variable is the average risk score in the market (county). Effects of lagged ($t - 1$) Medicare Advantage (MA) penetration are displayed. Contemporaneous effects are included in regressions but suppressed for readability. Regressions include interactions between the MA penetration variables and an indicator for high electronic health record (EHR) adoption by physician offices in the county. Data on EHR adoption were assembled by CMS and the Office of the National Coordinator for Health Information Technology (see Section A.9 for full details). Regressions additionally control for the corresponding contemporaneous (t) effects. Observations are county \times years. Controls are as described in Table 2. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table A7: Results by Profit Status

	Dependent Variable: County-Level Average Risk Score		
	(1)	(2)	(3)
MA Share, t-1	0.064** (0.012)	0.065** (0.012)	0.064** (0.012)
National For Profit MA Share, t-1	0.000 (0.010)		0.004 (0.010)
National Non Profit MA Share, t-1		-0.003 (0.013)	-0.006 (0.014)
Main Effects			
County FE	X	X	X
Year FE	X	X	X
Additional Controls			
State X Year Trend	X	X	X
County X Year Demographics	X	X	X
Observations	15,640	15,640	15,640

Note: The table reports coefficients from difference-in-differences regressions in which the dependent variable is the average risk score in the market (county). Effects of lagged ($t - 1$) Medicare Advantage (MA) penetration are displayed. Contemporaneous effects are included in regressions but suppressed for readability. The additional regressors in the table are the lagged MA enrollment share, as a fraction of Medicare eligibles, in large regional/national for-profit plans in the county \times year (column 1), in large regional/national not-for-profit plans in the county \times year (column 2), or in each separately (column 3). Because “main effects” for overall MA penetration are included in each regression, the coefficients on the for-profit and not-for-profit share variables can be interpreted as interaction terms that measure the difference in coding intensity for the indicated type of MA plan, relative to the excluded plan category, small and local plans. See Section A.10 for additional data notes. Observations are county \times years. Controls are as described in Table 2. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table A8: Heterogeneity in Effects by County Characteristics

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
MA Penetration t-1	0.119** (0.028)	0.062** (0.020)	0.026 (0.017)	0.089** (0.023)	0.120** (0.035)	0.012 (0.018)	0.060 (0.032)	0.077** (0.024)	0.128** (0.031)	0.061 (0.034)
High 2007 MA Pen. X MA Penetration t-1	-0.091** (0.031)				-0.082** (0.031)		-0.058* (0.029)		-0.076* (0.032)	-0.055 (0.030)
High ΔMA Pen. X MA Penetration t-1		-0.017 (0.026)			-0.027 (0.027)	0.016 (0.025)	0.004 (0.025)	-0.005 (0.028)		0.009 (0.026)
High ΔHHI X MA Penetration t-1			0.058* (0.023)			0.041 (0.023)	0.037 (0.023)			0.036 (0.023)
High Medicare Pop X MA Penetration t-1				-0.054* (0.022)				-0.046 (0.024)	-0.039 (0.023)	-0.010 (0.022)
Main Effects										
County FE	X	X	X	X	X	X	X	X	X	X
Year FE	X	X	X	X	X	X	X	X	X	X
Additional Controls										
State X Year Trend	X	X	X	X	X	X	X	X	X	X
County X Year Demographics	X	X	X	X	X	X	X	X	X	X
Mean of Dep. Var.										
Observations	15,640	15,640	14,370	15,640	15,640	14,370	14,370	15,640	15,640	14,370

Note: The table shows coefficients from difference-in-differences regressions in which the dependent variable is the average risk score in the market (county). Across the columns, specifications show how the effect varies with each of the interacted county-level variables: the 2007 level of MA penetration, the 2007 to 2011 change in MA penetration, the 2007 to 2011 change in HHI, and the 2007 size of the Medicare population. Indicators for above-median values of these variables are interacted with lagged MA penetration. Observations are county × years. Controls are as described in Table 2. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.

Table A9: Massachusetts Person-Level Analysis: Pre-Medicare Plan FEs

	Dependent Variable: Risk Score			
	(1)	(2)	(3)	(4)
Selected MA	-0.113** (0.007)		-0.116** (0.007)	
Post-65 X Selected MA	0.058** (0.009)	0.047** (0.007)	0.070** (0.011)	0.058** (0.009)
Person FE		X		X
Post-65 X Pre-65 Plan ID			X	X
Mean of Dep. Var.	1.00	1.00	1.00	1.00
Observations	319,094	319,094	319,094	319,094

Note: The table shows coefficients from difference-in-differences regressions described by Eq. 10 in which the dependent variable is the risk score. All regressions compare coding outcomes pre- and post-Medicare enrollment among individuals who select MA vs. individuals who select FFS. Data are from the Massachusetts All-Payer Claims Dataset. Pre-Medicare claims are from commercial/employer plans. Columns 2 and 4 include individual fixed effects. Columns 3 and 4 include fixed effects for the interaction of the person's pre-Medicare plan and an indicator for the post-Medicare enrollment period. Post-65 claims are from Medicare Advantage plans for MA enrollees and Medigap plans for FFS enrollees. The sample is restricted to individuals who join FFS or MA within one year of their 65th birthday and who have at least 6 months of continuous coverage before and after their 65th birthday. The unit of observation is the person-by-six month period, where six-month periods are defined relative to the month in which the individual joined Medicare. The coefficient on "Selected MA" should be interpreted as the pre-Medicare enrollment difference in the outcome for individuals who will eventually enroll in an MA plan vs. individuals who will eventually enroll in FFS. The coefficient on "Post-65 X Selected MA" should be interpreted as the differential change in the outcome post- vs. pre-Medicare for individuals who join an MA plan vs. individuals who join FFS. Data are described more thoroughly in Sections 7 and A.11. Standard errors in parentheses are clustered at the person level. * $p < 0.05$, ** $p < 0.01$.

Table A10: Massachusetts Person-Level Analysis: Heterogeneity by Pre-Medicare Health

	Sample Restriction:									
	Full Sample		No HCCs Pre-Medicare		Some HCCs Pre-Medicare		Below Top Quartile Score Pre-Medicare		Above Top Quartile Score Pre-Medicare	
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
Selected MA	-0.113** (0.007)		-0.015** (0.005)		-0.200** (0.017)		-0.019** (0.005)		-0.235** (0.023)	
Post-Medicare X Selected MA	0.058** (0.009)	0.047** (0.007)	0.020** (0.006)	0.034** (0.006)	0.108** (0.021)	0.056** (0.017)	0.022** (0.006)	0.028** (0.006)	0.138** (0.029)	0.078** (0.024)
Person FE	X		X		X		X		X	
Mean of Dep. Var.	1.00	1.00	0.72	0.72	1.22	1.22	0.76	0.76	1.84	1.84
Observations	319,094	319,094	203,923	203,923	115,171	115,171	239,916	239,916	79,178	79,178

Note: The table shows coefficients from difference-in-differences regressions described by Eq. 10 in which the dependent variable is the risk score. All regressions compare coding outcomes pre- and post-Medicare enrollment among individuals who select MA vs. individuals who select FFS. Data are from the Massachusetts All-Payer Claims Dataset. Pre-Medicare claims are from commercial/employer plans. Even columns include individual fixed effects. Columns 3-6 split the population based on whether they have any HCCs during the period just before entering Medicare. Columns 7-10 split the population based on whether their risk score during the period just before entering Medicare was in the top quartile. Post-65 claims are from Medicare Advantage plans for MA enrollees and Medigap plans for FFS enrollees. The sample is restricted to individuals who join FFS or MA within one year of their 65th birthday and who have at least 6 months of continuous coverage before and after their 65th birthday. The unit of observation is the person-by-six month period, where six-month periods are defined relative to the month in which the individual joined Medicare. The coefficient on “Selected MA” should be interpreted as the pre-Medicare enrollment difference in the outcome for individuals who will eventually enroll in an MA plan vs. individuals who will eventually enroll in FFS. The coefficient on “Post-65 X Selected MA” should be interpreted as the differential change in the outcome post- vs. pre-Medicare for individuals who join an MA plan vs. individuals who join FFS. Data are described more thoroughly in Sections 7 and A.11. Standard errors in parentheses are clustered at the person level. * $p < 0.05$, ** $p < 0.01$.

Table A11: Massachusetts Person-Level Analysis: Enrollment in MA and Utilization

	Dependent Variable:					
	Any Utilization		Any Inpatient Utilization		Any Other Utilization	
	(1)	(2)	(3)	(4)	(5)	(6)
Selected MA	-0.028** (0.002)		-0.021** (0.001)		-0.028** (0.002)	
Post-65 X Selected MA	0.064** (0.003)	0.072** (0.003)	-0.003* (0.002)	0.002 (0.002)	0.065** (0.003)	0.072** (0.003)
Person FE		X		X		X
Mean of Dep. Var.	0.89	0.89	0.04	0.04	0.89	0.89
Observations	319,094	319,094	319,094	319,094	319,094	319,094

Note: The table shows coefficients from difference-in-differences regressions described by Eq. 10 in which the dependent variable is an indicator for having any healthcare utilization during the period (columns 1 and 2), an indicator for having any inpatient utilization during the period (columns 3 and 4), and an indicator for having any non-inpatient utilization during the period (columns 5 and 6). Even columns include individual fixed effects. All regressions compare coding outcomes pre- and post-Medicare enrollment among individuals who select MA vs. individuals who select FFS. Data are from the Massachusetts All-Payer Claims Dataset. Pre-Medicare claims are from commercial/employer plans. Post-65 claims are from Medicare Advantage plans for MA enrollees and Medigap plans for FFS enrollees. The sample is restricted to individuals who join FFS or MA within one year of their 65th birthday and who have at least 6 months of continuous coverage before and after their 65th birthday. The unit of observation is the person-by-six month period, where six-month periods are defined relative to the month in which the individual joined Medicare. The coefficient on “Selected MA” should be interpreted as the pre-Medicare enrollment difference in the outcome for individuals who will eventually enroll in an MA plan vs. individuals who will eventually enroll in FFS. The coefficient on “Post-65 X Selected MA” should be interpreted as the differential change in the outcome post- vs. pre-Medicare for individuals who join an MA plan vs. individuals who join FFS. Data are described more thoroughly in Sections 7 and A.11. Standard errors in parentheses are clustered at the person level. * $p < 0.05$, ** $p < 0.01$.

Table A12: Massachusetts Person-Level Analysis: Conditional on Pre-Medicare Utilization

	Dependent Variable:			
	Risk score		Risk score (cond'l on use)	
	(1)	(2)	(3)	(4)
Selected MA	-0.113** (0.007)		-0.115** (0.008)	
Post-65 X Selected MA	0.058** (0.009)	0.047** (0.007)	0.033** (0.01)	0.036** (0.008)
Person FE		X		X
Mean of Dep. Var.	1.00	1.00	1.05	1.05
Observations	319,094	319,094	282,379	282,379

Note: The table shows coefficients from difference-in-differences regressions described by Eq. 10 in which the dependent variable is the risk score. All regressions compare coding outcomes pre- and post-Medicare enrollment among individuals who select MA vs. individuals who select FFS. Data are from the Massachusetts All-Payer Claims Dataset. Pre-Medicare claims are from commercial/employer plans. Columns 2 and 4 include individual fixed effects. Columns 1 and 2 replicate the main results from Table 5. Columns 3 and 4 restrict to person-periods with some healthcare utilization. Even columns include individual fixed effects. Post-65 claims are from Medicare Advantage plans for MA enrollees and Medigap plans for FFS enrollees. The sample is restricted to individuals who join FFS or MA within one year of their 65th birthday and who have at least 6 months of continuous coverage before and after their 65th birthday. The unit of observation is the person-by-six month period, where six-month periods are defined relative to the month in which the individual joined Medicare. The coefficient on “Selected MA” should be interpreted as the pre-Medicare enrollment difference in the outcome for individuals who will eventually enroll in an MA plan vs. individuals who will eventually enroll in FFS. The coefficient on “Post-65 X Selected MA” should be interpreted as the differential change in the outcome post- vs. pre-Medicare for individuals who join an MA plan vs. individuals who join FFS. Data are described more thoroughly in Sections 7 and A.11. Standard errors in parentheses are clustered at the person level. * $p < 0.05$, ** $p < 0.01$.

Table A13: Selection Results: Effects on within-FFS and within-MA Risk Scores

	Dependent Variable:					
	Mean FFS Risk Score			Mean MA Risk Score		
	(1)	(2)	(3)	(4)	(5)	(6)
MA Penetration t	0.037 (0.026)	0.040 (0.034)	0.040 (0.033)	0.025 (0.062)	-0.024 (0.085)	-0.013 (0.083)
MA Penetration t-1	0.045** (0.013)	0.030* (0.012)	0.026* (0.012)	0.087* (0.040)	0.116** (0.040)	0.130** (0.041)
Main Effects						
County FE	X	X	X	X	X	X
Year FE	X	X	X	X	X	X
Additional Controls						
State X Year Trend		X	X		X	X
County X Year Demographics			X			X
Dep var mean	1.006	1.006	1.006	0.959	0.959	0.959
Observations	15,640	15,640	15,640	15,616	15,616	15,616

Note: The table shows coefficients from difference-in-differences regressions in which the dependent variables are the average FFS risk score in the county (columns 1 through 3) and the average MA risk score in the county (columns 4 through 6). Both contemporaneous and lagged coefficients represent tests of selection. Observations are county \times years. Controls are as described in Table 2. Standard errors in parentheses are clustered at the county level. * $p < 0.05$, ** $p < 0.01$.